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Parkinson's disease (PD) is a progressive movement disorder characterized by degeneration 
of dopaminergic neurons of the substantia nigra pars compacta (SNpc). The mean age of PD 
patients at the onset of motor signs is in the seventh decade of life (prevalence is about 1% 
at age 65, 5% at age 85), but an estimated 3% of cases are initially recognized in individuals 
younger than age 50. PD is mostly sporadic, although genetic forms of the disease are 
known. In particular, 20% of PD cases are genetic forms, and are found more frequently in 
patients with onset before 50 years. 
The diagnosis is currently based on clinical manifestations of the disease, but 70% of nigral 
neurons are lost when symptoms appear. Late diagnosis hampers clinical development of 
new disease-modifying therapies; only alleviating symptoms is possible at present. For this 
reason, great interest in developing peripheral biomarker for PD has increased. In particular, 
such biomarker should be: (1) specific for PD, (2) able to monitor the progression of the 
disease, (3) providing no discomfort for the -potential- patients, (4) available at an accessible 
cost for a population screening. 
 
The immune system may possibly reflect specific mechanisms of PD pathogenesis occurring 
at the central level. In fact, peripheral blood cells have been shown to share some of the 
changes exhibited by nigral neurons. In particular, T-lymphocytes express some features of 
the dopaminergic system: they express dopamine receptors, membrane and vesicular 
transporters, they store catecholamines into vesicles and - only the T regulatory subset - 
release it as co-stimulatory signal for other immune cells. 
On this basis, our group proposed that T-lymphocytes may constitute an amenable and 
easily accessible source of peripheral biomarkers for PD, where the dopaminergic system is 
impaired.  In particular, patients affected by familial forms of PD (about 20% of all PD cases) 
may express, also at the peripheral level, genetic alterations that mirror the pathogenic 
process at the central level. 
To investigate differences between patients and people not affected by PD, we used a global 
and unbiased approach: the proteomic approach permitted us to gain a view of T 
lymphocytes’ proteome and to compare cells from patients and control subjects (healthy 





We enrolled 15 PD patients and 17 control subjects (14 healthy subjects and 3 affected by 
atypical parkinsonisms). The group of patients was enriched with Early Onset PD patients, 
who have a greater probability to be affected by a genetic form of the disease, in order to 
highlight possible effects due to the genetic background. All subjects underwent a venous 
blood sampling, then T-lymphocytes were collected and isolated. Protein expression 
differences were evaluated using two-dimensional electrophoresis (2-DE). 
A statistical analysis was conducted in order to (1) find significant differences between 
patients and control subjects, (2) calculate a function that, taking into account contributes of 
changing spots, was able to rightly predict patients and controls, (3) identify spots 
correlating with other parameters of disease: duration, gravity of symptoms, age at onset. 
Wilcoxon test was applied on spots from maps of PD patients and control subjects, after 
elimination of spots correlating with confounding factors such as therapy and age; we found 
20 proteins whose level was significantly different in PD patients and controls (p<0.05): their 
relative volumes were combined by Linear Discriminant Analysis so to obtain a likelihood 
score (PD Score) for each subject. PD scores were significantly different in PD patients with 
respect to control subjects (Wilcoxon test, p < 10-8); performance of the model was tested 
with the leave-one-out method (87% sensitivity, 81% specificity). We eliminated from the 
dataset those spots whose contribution to the LDA function was lower and we obtained a 
better model with 100% sensitivity and 94% specificity. A third model with a lower number 
of spots has been proposed (100% sensitivity and 88% specificity). 
These 20 spots were also evaluated for the occurrence of correlation with time or disease 
severity, in order to propose biomarkers of PD progression. Correlation with the Hoehn and 
Yahr score (parameter used to assess gravity of symptoms) was observed for 8 spots; 4 spots 
correlate with duration (years of disease). Both the correlations were evaluated as Pearson 
linear correlation (r = 0.603, p < 0.0005 and r = 0.548, p = 0.001, respectively). 
Also the parameter “age at onset” was evaluated: we divided patients into two groups: early 
onset PD patients (EOPD, age at onset before 45 years) and late onset PD patients (LOPD, 
age at onset after 45 years), than we compared the two groups: we found 7 quantitative 
protein differences (Wilcoxon test, p = 0.006). 
All the spots of the models or showing correlation with one of the mentioned parameters 
were excised from the gels and identified by LC-MS/MS fragmentation: some of the most 




4 spots correspond to beta fibrinogen and 2 spots correspond to transaldolase; all together, 
these 6 spots contribute to the prediction model in a very remarkable way.  
For this reason, we validated by Western blot total beta fibrinogen and transaldolase 
changes to verify their proper identification and confirm the differences observed by 2-DE 
with another technique (Western blotting). 
Worth of note, the level of some proteins was modified by levodopa and dopamine agonists 
therapy in T lymphocytes: this is a demonstration that these cells are sensitive to long term 
dopaminergic stimulation and that they are a valid tool to investigate dopaminergic 
imbalance at a peripheral level. 
Additional experiments were conducted in order to deepen the role of fibrinogen in T cells, 
and the reason why its volume is reduced in PD patients: this study is currently going on, but 
preliminary results indicate that it is internalized by T cells from plasma. 
 
In conclusion, in this thesis T lymphocyte proteome changes have been shown to be a valid 
tool to recognize and classify PD patients. It has been proposed a model using a rationale of 
similarity between affected cells (dopaminergic neurons) and probed system (T 
lymphocytes): we expect that our system will reasonably provide information on the 
effectiveness of future (or under development) drugs designed to interfere with specific cell 
death mechanisms targeting nigral neurons. Moreover, our system possess most features 
required for candidate PD biomarkers (specificity, indication of progression, accessibility). 
Next step of this research is leading the current finding to the clinical practice. This objective 
will be reached only through large collaborative networks, that will allow us to select large 
cohorts of subjects with high heterogeneity in terms of gender, age, ethnicity, clinical 

















1.1  PARKINSON’S DISEASE 
 
Parkinson’s Disease (PD) is the second most common movement disorder after Alzheimer’s disease, 
affecting about 6 million people worldwide (Shulman et al., 2011). 
PD is typically a chronic and slowly progressive disorder. Cardinal manifestations  include resting 
tremor, bradykinesia (slowed movements), rigidity (increased muscular tone), postural instability, 
and gait impairment. They are attributable to dopaminergic cell loss within the substantia nigra pars 
compacta (SNpc)  and resultant dysfunction of the basal ganglia, a cluster of deep nuclei that 
participate in the initiation and execution of movements (Shulman et al., 2011). 
In the later stages of the disease the symptoms are accompanied by postural instability and, in some 
cases, by cognitive impairment. As PD progresses, other symptoms like pain, sensory complaints, 
autonomic dysfunction, neuropsychiatric manifestations (depression, hallucinations, and dementia) 
become prominent: these features are probably due to the spread of pathology beyond the basal 
ganglia (Jankovic 2008).The progression of the disease is evaluated through clinical parameters. The 
Unified Parkinson’s Disease Rating Scale (UPDRS) was developed as an effort to incorporate different 
elements of PD impairment and disability. It is divided into four components: Part I, mentation, 
behavior and mood; Part II, activities of daily living; Part III, motor; Part IV, complications (Goetz et 
al., 2007). A simplified way to clinically evaluate PD stages is the Hoehn and Yahr scale, modified by 
the Movement Disorder Society Task Force for Rating Scales for Parkinson’s disease (Goetz et al., 
2004) (Table 1). 
 
Table 1: Modified Hoehn and Yahr scale. Point 1.5 and 2.5 were inserted in revision of 2004 with 
respect to the original scale published in 1967 (Goetz et al., 2004). 
 
Modified Hoehn and Yahr scale 
1.0 Unilateral involvement only 
1.5 Unilateral and axial involvement 
2.0 Bilateral involvement without impairment of balance 
2.5 Mild bilateral disease with recovery on pull test 
3.0 
Mild to moderate bilateral disease; some postural instability;  
physically independent 
4.0 Severe disability; still able to walk or stand unassisted 







1.1.1 Epidemiology  
With a prevalence of approximately 1% at age 65, which rises to nearly 5% at age 85, PD is the 
second most common neurodegenerative disorder after Alzheimer’s disease (Shulman et al., 2011). 
A number of epidemiological factors have been proposed to increase PD risk: 
- age: PD can be diagnosed at any age, but the mean age of PD diagnosis is in the seventh decade of 
life; only an estimated 3% of cases are initially recognized in individuals younger than age 50 
(Shulman et al., 2011). In a epidemiological study carried on the basis of data from Kaiser 
Permanente Medical Care Program, Northern California, it has been shown how the incidence rates 
rose rapidly after the age of 60 years, going from 0.50 per 100,000 in the fourth decade to 107.2 
per 100,000 in the eighth decade (Van Den Eeden et al., 2003).  
- Gender: there is a greater incidence of PD in men than in women; rate ratios of different studies 
have been compared in two meta-analysis, which reported similar age-adjusted male:female 
incidence of 1.49 (95% confidence interval (CI) 1.24–1.95, p = 0.031) and 1.46 (95% CI 1.24–1.72, p 
< 0.001) (Pavon et al., 2010). Neuroprotective effects of estrogens have been suggested as a 
possible explanation for this difference in gender incidence, but their role is still controversial 
(Saunders-Pullman 2003; Cordellini et al., 2011). 
- Family history: about 20% of PD subjects reported a positive family history; more details are 
presented in the chapter “Genetics”. 
- Occupational exposures: in 1983 it was surprisingly discovered that the toxin MTPT was able to 
selectively damage dopaminergic cells in the Substantia Nigra and induce typical signs of PD in 
humans; some pesticides and herbicides, like rotenone and paraquat, have been found to have the 
same mechanism of action of MTPT in animals (Betarbet et al., 2000). Since then, many 
epidemiological studies have been done to examine the association between exposure to such 
substances, as well as hypothesized surrogate measures, such as farming, living in rural areas, and 
drinking of well water, and the risk of PD. The relation between (self-reported) pesticide exposure 
and plantation work and PD has only been examined prospectively in one large study among men 
(Petrovitch et al., 2002). A significantly increased risk of PD was found among men who worked for 
more than 10 years on a plantation, and a non significant association for men exposed to 
pesticides.  
- Dietary and habitual factors: both cigarette smoking and coffee consumption are associated with 
reduced PD susceptibility (de Lau and Breteler, 2006). 
Ultimately, however, epidemiological association does not necessarily imply causation, but the 
potential yield of these cohort studies is of high importance in better understanding mechanisms of 




1.1.2  Pathology and pathogenesis 
The cardinal neuropathological feature of PD is dopaminergic cell loss within the SNpc. Because 
dopaminergic cells contain melanin, cell loss within the SNpc is accompanied by depigmentation of 
the midbrain, that is readily visible in gross material postmortem. Surviving neurons appear rich in 
intracytoplasmic inclusions termed Lewy Bodies (Spillantini and Goeder, 2000). 
 
 
Fig. 1: Anatomy and physiology of PD motor manifestations. A simplified 
schematic of the neuronal circuits involving the basal ganglia, thalamus, and 
cortex and their derangement in PD. It normally functions to facilitate 
movements (left), but in PD the output is attenuated (right). The midbrain 
substantia nigra pars compacta (SNc) provides dopaminergic input to the 
putamen (Pu), which is excitatory to the direct pathway. The putamen 
inhibits (red ) the globus pallidus interna (GPi), which subsequently inhibits 
the thalamus (Th). The thalamus projects excitatory input (green) to the 
motor cortex. In PD, degeneration within the SNc leads to net increased 
inhibition of the thalamocortical projection. Taken from Shulman et al., 2011. 
 
 
Dopaminergic neurons in the SNpc project primarily to the striatum, (Fig. 1) therefore, nigral cell loss 
result in the depletion of striatal dopamine. Decreased nigrostriatal input leads to a net increase of 
inhibitory output from the globus pallidus interna to the thalamus and, indirectly, to the cortex, 
thereby repressing the initiation of movements and leading to the characteristic motor 
manifestations (Shulman et al., 2011).LB are spherical and eosinophilic inclusions, mainly composed 




individuals with PD are additionally characterized by α-synuclein-positive accumulations within 
neuronal processes, termed Lewy neurites (Spillantini and Goeder, 2000; Shulman et al., 2011). α-Syn 
is a small protein of 140 amino acids, whose function is not completely understood so far. Its 
conformation can range from unfolded state in solution, to α-helical in the presence of lipid-
containing vesicles, to β-pleated sheet or amyloid structure in fibrils (McNaught and Olanow, 2006). 
Given the positivity for α-syn in LB and Lewy neurites, and the fact that mutations in the α-syn gene 
cause rare familial forms of PD (see below), it was initially suggested that the accumulation of α-syn 
might cause the selective degeneration of dopaminergic neurons (Thomas and Beal, 2007; Fasano 
and Lopiano, 2008). On the other hand, α-syn expressed at low levels appears to be neuroprotective 
and anti-apoptotic in dopaminergic neurons, indicating a dual role for this protein (Colapinto et al., 
2006; Cookson 2006). Several lines of evidence suggest that the upregulation of α-synuclein 
represents a compensatory mechanism adopted by neurons to protect themselves from chronic 
oxidative stress (Alberio et al., 2010).Molecular mechanisms leading to degeneration of SNpc 
neurons are not fully understood. A number of evidences indicate some factors important for the 
final degeneration, but temporal and mechanistic relationships among them are not well 
characterized. Major factors have been identified as mitochondrial impairment, ubiquitin-
proteasome dysfunction, altered calcium homeostasis and oxidative stress (Banerjee et al., 2009; 
Surmeier et al., 2010; Alberio and Fasano, 2011).  
Nigral dopaminergic neurons are particularly susceptible to oxidative stress because of their 
exposure to a high oxidative load: first of all, the metabolism of dopamine gives rise to various 
molecules that can act as endogenous toxins and start the formation of oxygen reactive species 
(ROS). Normally, these species are eliminated by intracellular antioxidant systems, which might be 
impaired by aging or by specific alterations owing to the disease pathogenesis (Alberio and Fasano, 
2011). 
For instance, dopamine (DA), that is normally stored into acidic vesicles, can autooxidize to dopamine 
quinone and hydrogen peroxide when it is released into the neutral pH cytoplasm. The release is 
usually avoided, but it could occur when the system of vesicles is damaged; in this context, -syn has 
a role in vesicular trafficking, and when -syn is overexpressed and accumulate into the cells, it starts 
to aggregate into protofibrils (the toxic species) and fibrils (as observed in LB) (Bisaglia et al., 2010). 
Protofibrils are able to form pores through membranes of vesicles, permitting DA to exit and form 
cytotoxic hydroxyl radicals in a reaction catalyzed by iron, the levels of which are higher in SNpc than 
in other brain regions (Fasano et al., 2006). Moreover, dopamine quinone reacts with alpha-synuclein 
to form covalent adducts that slow the con-version of toxic protofibrils to fibrils, shifting the 




Iron also seems to play a key role in the increased susceptibility of these pigmented, neuromelanin 
(NM)-containing neurons, and the dopamine-derived NM pigment appears to be a critical regulator 
of iron homeostasis (Fasano et al., 2006).  
The increased susceptibility of dopaminergic SNpc neurons has also been associated to their 
morphology: they have long, thin, poorly myelinated and branched projections, thus accounting for a 
peculiar need for mitochondrial activity with a consequent higher ROS production (Thomas and Beal, 
2007). Furthermore, dopaminergic SNpc neurons maintain their basic activity through L-type calcium 
channels instead of sodium channels, a situation that needs an increased ATP production to control 
calcium homeostasis and, at the same time, exposes cells to elevated mitochondrial oxidative stress 
(Surmeier et al., 2010). 
Mitochondria are a major source of free radicals in the cell, causing the appearance or the increase 
of oxidative stress conditions. They also sequester calcium when intracellular calcium levels rise 
during the excitotoxic process. The threshold for excitotoxicity might decrease if mitochondrial ATP 
production is impaired. Mitochondria also have a pivotal role in apoptotic cell death: release of the 
pro-apoptotic factor cytochrome c, usually associated with the inner membrane of the 
mitochondrion, into the cytoplasm triggers a cascade of events, culminating in cell death (Henchcliffe 
and Beal, 2008). Strong evidence exists to support a role for aberrant mitochondrial form and 
function in the pathogenesis of PD (Schapira 2011): for instance, activity of the mitochondrial 
respiratory complex I (NADH-quinone oxidoreductase) is reduced in the substantia nigra of PD 
patients (Schapira et al., 1990). Another indication of mitochondrial implication in PD pathogenesis is 
given by genetic evidences of PD-causing mutations in genes of mitochondrial proteins (see below). 
As a whole, in a disease where the etiology is still largely unknown, many of the genetic and 
environmental factors variously linked to it contribute to a redox imbalance that seems to have the 
strongest effect on the more sensitive dopaminergic SN cells (Alberio et al., 2012a).  
 
 
1.1.3  Genetics  
According to recent epidemiological studies, 10–30% of PD subjects reported a positive family 
history, and first-degree relatives of subjects with PD were estimated to have a twofold- to 
sevenfold-increased relative risk of PD. In many cases, penetrance is not complete, thus accounting 
for an intrinsic difficulty in their identification (Shulman et al., 2011). 
Autosomal recessive forms of parkinsonism are linked to mutations in parkin (PARK2, the most 
common), PINK1 (PTEN-induced putative kinase 1; PARK6), DJ-1 (PARK7), ATP13A2 (PARK9), PLA2G6 
(PARK14) and FBXO7 (PARK15) genes, and are characterized by age at onset usually before 40 years. 




PINK1, DJ- 1 and maybe ATP13A2) all belong to the pathway aimed at the elimination of damaged 
mitochondria. Carriers of these mutations display the upsurge of PD motor symptoms before 50 
years of age and the available post-mortem studies often show an atypical PD pathology in that Lewy 
bodies (LB) may be absent (Shulman et al., 2011). 
To what concerns autosomal dominant forms, mutations in six genes have been identified: SNCA 
(coding for -syn; PARK1 for point mutations, PARK4 for duplication or triplication of the gene), 
UCHL1 (ubiquitine C-terminal ligase L1; PARK5), LRRK2 (leucine-rich repeat kinase 2; PARK8), GIGYF2 
(PARK11), OMI/HtrA2 (PARK13) and the recently discovered GBA. (Gasser 2009; Shulmann et al., 
2011; Alberio et al., 2012a). LRRK2 mutations are the most common cause of dominant familial PD, 
accounting for 1% of sporadic PD cases (Shulman et al., 2011). 
 
 
Table 2. Parkinson’s disease-related proteins. Gene and protein names are indicated for genetic PD 
forms. For gene products, official Uniprot protein names are listed. Proteins are cited in the 
text using their aliases. Adapted from Alberio et al., 2012a. 
PARK locus Gene name Gene product Alias 
PARK1 ⁄ PARK4  SNCA Alpha-synuclein α-synuclein 
PARK2 PARK2 E3 ubiquitin-protein ligase parkin PARKIN 
PARK5 UCHL1 
Ubiquitin carboxyl-terminal hydrolase isozyme L1 
(UCH-L1) 
UCH-L1 
PARK6 PINK1 Serine ⁄ threonine-protein kinase PINK1 PINK1 
PARK7 PARK7 Protein DJ-1 DJ-1 
PARK8 LRRK2 
Leucine-rich repeat serine ⁄ threonine-protein 
kinase 2 
LRRK2 
PARK9 ATP13A2 Probable cation-transporting ATPase 13A2 ATP13A2 
PARK11 GIGYF2 
PERQ amino acid-rich with GYF domain-
containing protein 2 
GIGYF2 
PARK13 HTRA2 Serine protease HTRA2 (HtrA2) HtrA2 
PARK14 PLA2G6 
85 kDa calcium-independent phospholipase A2 
(IPLA2) 
IPLA2 
PARK15 FBXO7 F-box only protein 7 FBXO7 
PARK17 VPS35 













Although the different mutations and loci identified so far appear to be directly responsible in only a 




identified may be common to more than one genetic form of PD and may also play a role in the 
common sporadic disease (Gasser 2009).  
Worth of note, patients with onset before age 45 (Early Onset PD Patients, EOPD) have more 
frequently a positive family history, and consequently an increased likelihood of a genetic etiology 
compared with patients with late-onset PD (LOPD), though also late-onset PD may have a substantial 
familial component (Payami et al., 2002). 
 
 
1.1.4  Therapy 
Motor symptoms respond well to dopamine replacement therapy, which has been the pillar of PD 
treatment since its introduction (late 1960). Although currently available PD therapies both delay 
disability and prolong life expectancy, none has been proven to significantly alter the ongoing 
neurodegenerative process (Rascol et al., 2011). 
The dopamine precursor L-dihydroxyphenylalanine (L-DOPA) represents the most effective 
treatment. The addition of a peripheral dopa decarboxylase inhibitor enhances the therapeutic 
benefit of L-DOPA and prevents peripheral effects. However, chronic oral treatment with L-DOPA is 
associated with the development of motor complications: fluctuations in motor performance, 
reflecting rises and falls of L-DOPA plasma levels (“on”/“off” states), L-DOPA induced involuntary 
movements and painful dystonia. The exact pathophysiology of these L-DOPA related motor 
complications still remains incompletely understood (Rascol et al., 2011). Improvements in 
pharmacokinetic have been reached with continuous duodenal L-DOPA infusions (Kurlan et al., 
1986), but system-related complications such as occlusions or dislocation of catheters, local 
inflammation around the gastrostomy site, and mechanical pump problems, together with high 
costs, still limit the broad-scale use of this approach (Rascol et al., 2011). 
Another important category of antiparkinsonian drugs is represented by dopamine agonists, which 
can be used as monotherapy or in combination with L-DOPA. They exert their action by directly 
activating DA receptors , bypassing the presynaptic synthesis of DA. The activation of D2-like 
receptors (especially D3) is important for antiparkinsonian effects of dopamine agonists, although 
concurrent D1-like and D2-like stimulation is required to produce optimal physiological and 
behavioral effects (Jankovic and Aguilar, 2008). Some commonly used dopamine agonists in the 
clinical practice are Ropinirole, Pramipexole and Rotigotine. 
Other strategies to prolong DA response make use of inhibitors of enzymes that metabolize 
dopamine, such as catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). When 
used in combination therapy, they extend the duration of action of L-DOPA. COMT inhibitors are 




Unfortunately, most nonmotor symptoms, that are due to degeneration of more diffuse areas than 
SN, show little or no response to dopamine replacement and contribute substantially to overall 
disability, especially late in disease. In advanced disease, direct modulation of basal ganglia activity 
via deep brain stimulators implanted in the subthalamic nucleus can also be effective (Shulman et al., 
2011; Zibetti et al., 2011).  
Although currently available PD therapies both delay disability and prolong life expectancy, none has 
been proven to significantly alter the ongoing neurodegenerative process (Shulman et al., 2011; 
Alberio and Fasano 2011). 
 
 
1.1.5  Diagnosis 
PD can be diagnosed at any age, but the mean age of PD diagnosis is in the seventh decade of life; 
however, due to PD’s insidious nature, the onset of symptoms may precede clinical recognition by 
many years (Shulman et al., 2011). Given the aging population, the prevalence of PD is anticipated to 
increase dramatically, which would lead to increased urgency for the need to identify improved 
therapies that delay progression and mitigate disability.  
The diagnosis is currently based on clinical manifestations of the disease, but 60% of dopaminergic 
neurons, which is paralleled by the loss of 80% of dopamine in the striatum, are lost when motor 
symptoms appear, rendering difficult protective or restorative therapies in a such advanced stage of 
neurodegeneration (Shulman et al. 2011). 
Diagnostic features of PD are asymmetrical onset, rigidity, bradykinesia, unilateral tremor at rest and 
acute L-DOPA response. Additional non motor symptoms, such as impaired olfaction, disordered 
sleep and constipation appear several years before motor symptoms, but are unspecific and difficult 
to detect (Shulman  et al., 2011). The picture is made more complicated by a large heterogeneity in 
terms of predominance of one of the motor symptoms over the others and in terms of disease 
progression. Misdiagnosis rate ranging from 10% (diagnosis performed by movement disorders 
experts) to 50% (as it is the case with primary healthcare) (Tolosa et al. 2006). The occurrence of 
tremor may be of iatrogenic or psychogenic origin, and patients affected by essential tremor are 
sometimes erroneously diagnosed as PD patients. Likewise, the occurrence of parkinsonian signs is 
common also in other neurodegenerative disorders, named atypical degenerative parkinsonisms 
(ATP) for the similarity of initial symptoms (Shulman et al.,  2011).  
These syndromes are less frequent than PD, and have different pathologies. The most frequent 
atypical parkinsonian disorders are progressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD), multiple system atrophy (MSA) and dementia with Lewy bodies (LBD) .MSA is a rapidly 




urinary incontinence and orthostatic intolerance, accompanied by parkinsonism and/or cerebellar 
dysfunction and associated with glial α-syn inclusion pathology (Jecmenica-Lukic et al., 2012). PSP is a 
neurodegenerative tauopathy which can manifest clinically in a variety of syndromes, in particular 
one of them begin with same symptoms of PD and is responsive to L-DOPA (Boeve 2012). 
Diagnosis is helped by molecular imaging with positron (PET) or single photon (SPECT) emission 
tomography. These techniques provide information on presynaptic dopaminergic function through 
emission of 6-[18F]fluoro-L-dopa (FD) or 6-[18F]fluoro-m-tyrosine (FMT), used as radiotracer of the 
vesicular monoamine transporter type 2 (VMAT2) and the plasmalemmal dopamine transporter 
(DAT). In PD, substantial reductions in tracer uptake is observed: while this pattern is typical of PD, it 
may be also seen in MSA and in parkinsonism associated with spinocerebellar atrophy, and is 
accordingly not sufficient to robustly differentiate PD from other akinetic-rigid syndromes. (Stoessl 
2012). 
Objective, accessible, and easily measurable biologic parameters, correlating either with the 
presence or the severity of PD, are a major prerequisite for a more refined diagnosis and the 
development of novel therapeutic strategies. Currently, there is no reliable biomarker for PD, neither 
markers exist to objectively measure the severity and the rate of progression of PD-related cellular 
dysfunction and neurodegeneration in the substantia nigra.  
The availability of peripheral PD biomarkers would have a dramatic feedback (Fig. 2). They would 
allow the differentiation of susceptible individuals from normal ones before motor symptoms appear 
(early diagnosis), and would help the identification of true idiopathic PD from atypical degenerative 
parkinsonisms (differential diagnosis). Moreover, the differentiation of patients in terms of their 
response to a pharmacological treatment would be possible (therapy assessment) (Michell et al., 
2004). It would be desirable to have available a panel of biomarkers that not only allow the diagnosis 
of PD at an early, pre-motor stage, but possibly correlate with the progression of the 
neurodegeneration progress. This would allow researchers to develop neuroprotective or 
neurorestorative agents and to follow directly their efficacy. Although restorative therapies are still 
far from actuality, clinical trials on new PD treatments cannot be foreseen in the absence of 





Fig. 2: Peripheral biomarkers are required to accomplish different tasks: early 
diagnosis, possibly at a pre-motor stage; differential diagnosis of 
parkinsonian syndromes and of PD subtypes that may require different 
therapeutic plans; assessment of a personalized therapeutic plan; objective 
measurement of the actual extent of neurodegeneration so that 
neuroprotective and/or neurorestorative interventions could be monitored 







1.2  A POTENTIAL SOURCE FOR BIOMARKERS OF PD: PERIPHERAL 
T LYMPHOCYTES 
 
Besides of its action on the nervous system, DA has been identified in other organs and tissues, 
including the vascular beds, the hearth, the gastrointestinal tract, and the kidney. Moreover, a 
number of studies showed DA components in the immune system, and suggested that DA plays a key 
role on neural-immune interactions and immune cells in particular (Pacheco et al., 2009; Buttarelli et 
al., 2011; Sarkar et al., 2010).  
 
 
1.2.1  The dopaminergic system in peripheral blood lymphocytes 
The original discovery of endogenous DA in PBL was made by Bergquist et al. (Bergquist et al., 1994). 
The authors applied capillary electrophoresis, and subsequently electrospray ionization mass 
spectroscopy (Bergquist and Silberring, 1998), to quantify DA and its metabolites in peripheral blood 
lymphocytes (PBL). Moreover, they observed reduced catecholamine levels after pharmacological 
inhibition of tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of catecholamines, 
by α-methyl-p-tyrosine, suggesting direct synthesis of catecholamines by PBL, while intracellular DA 
levels were increased by exposure to extracellular DA, suggesting also the presence of an active 
cellular uptake mechanism. In a different study, it was shown that T-lymphocytes contained L-DOPA 
and norepinephrine, whereas B-lymphocytes contained only L-DOPA. (Musso et al., 1996). 
Catecholamine (including DA) synthesis by human PBL was confirmed in 2004 (Qiu et al., 2004). 
Subsequently, Cosentino and coworkers showed that a subset of human T-lymphocytes, CD4+CD25+ 
regulatory T lymphocytes (Treg), but not other subtypes (e.g., effector T-lymphocytes, Teff), 
constitutively express TH; moreover, they contain substantial amounts of DA, epinephrine and 
norepinephrine, which may be released upon treatment with reserpine (Cosentino et al., 2007).  
Despite such converging evidence for the presence in PBL of catecholamines (of DA in particular), 
characterization of DA receptors has been more difficult. After many years of rather contradictory 
results, the presence of DA receptors in PBL was confirmed (McKenna et al., 2002).  
Confocal laser microscopy demonstrated the presence and localization of vesicular monoamine 
transporter 2 (VMAT-2): its immunoreactivity was appreciable mainly in cytoplasmic puntiform areas, 
that were likely to correspond to vesicles, and to a lower extent was associated to plasma 
membrane, whereas DAT and VMAT-1 immunoreactivities were located almost exclusively in PBL 




1.2.2  Physiology and pharmacology of DA system in immune cells 
By stimulating DA receptors expressed on PBL membrane, DA from diverse sources (plasma, 
sympathetic nervous system, autocrine or paracrine secretion by immune cells, CNS) may contribute 
to regulate the initiation and development of immune responses (Pacheco et al., 2009). 
The stimulation of D1-like receptors, and the consequent increase of intracellular cAMP, determines 
the inhibition of cytotoxic CD8+ cells, impairs function and differentiation of  Treg cells, and induces 
polarization of naive CD4+ cells toward T-helper 17 (Th17) phenotype (Besser et al., 2005). Because 
Th17 and Treg are involved in autoimmunity as auto-aggressive and beneficial cells respectively, it is 
likely that D1-like receptors expressed on T-cells are involved in the interface between autoimmunity 
and health. Interestingly, the decreased expression of D5 receptors in PBL has been found in patients 
suffering from multiple sclerosis (Giorelli et al., 2005). 
D2-like receptors, which stimulation results in decreased intracellular cAMP, are also involved in the 
modulation of T-cells physiology: stimulation of D3 receptors controls T-cell adhesion and migration 
and induces differentiation of naive CD8+ cells into cytotoxic T-lymphocytes (Besser et al., 2005); on 
the other hand, it also contributes to polarization of naive CD4+ cells toward T-helper 1 phenotype 
(Ilani et al., 2004). Eventually, D2 and D4 receptors regulate the activation and differentiation of 
naive CD4+ cells, for example, by promoting the polarization toward Treg cells (D2) or by triggering T-
cell quiescence (D4) (Pacheco et al., 2009; Sarkar et al., 2010). 
 
 
1.2.3  Changes of PBL dopaminergic system in PD 
Following the characterization of the DA system in human PBL, the question raised of whether PBL 
may represent a useful cellular model with which to investigate the derangement of DA transmission 
in patients suffering from neurological or psychiatric disorders. Because of the prominent role of DA 
derangement in parkinsonian syndromes, most studies were centered on PD. Nagai reported the 
statistically significant decrease of the D3 receptor mRNA expression in PBL from PD patients (Nagai 
et al., 1993), while Barbanti  showed that PBL from PD patients have a higher density of both D1-like 
and D2-like binding sites than those of neurological or healthy control subjects (Barbanti et al., 1999). 
Reduction of intracellular DA concentration and TH immunoreactivity in PBL from PD patients with 
respect to healthy subjects has been observed as well as reduction of DAT immunoreactivity in PBL 
from de novo PD patients (Caronti et al., 1999). 
Regarding protein level alterations in PBL, a preliminary investigation on PBL of advanced PD patients 
has demonstrated that a proteomic profiling based on 2-DE highlights differences at the peripheral 
level between patients and control subjects. This panel of proteins included cofilin 1, a basic actin 




Taken together, the results from a number of studies support the hypothesis that PBL may represent 
a useful tool for investigating the changes of DA system in CNS pathologies, as well as to monitor the 
consequences of pharmacological manipulations of DA transmission (Alberio and Fasano, 2011). This 
is particularly relevant in the case of patients carrying a familiar form of the disease, in which gene 
expression of patterns implicated in pathological mechanisms damaging selectively dopaminergic 
neurons could be appreciated also in peripheral dopaminergic cells. T lymphocytes are the 
population of immune cells that better could reflect some of the alterations that impair the function 
of SNpc dopaminergic neurons at a peripheral level, because they express some dopaminergic 
features (receptors, transporters, vesicles) and because DA plays an active role in their functions, as 









1.3  THE PROTEOMIC APPROACH 
 
Proteomics is the study of both the structure and function of proteins by a variety of methods. 
Originally proposed as the protein complement of the genome, the proteome assumed in more 
recent times a more functional significance (Alberio and Fasano, 2011). No limitations are set in 
terms of cellular functions or specific signal transduction pathways, thus enabling the investigation of 
proteins that are not a priori expected to be linked to any condition. Intrinsically, proteomics is an 
unbiased approach, aimed at generating a list of candidate proteins deserving further targeted 
studies. Such a global approach allows to manage with the great complexity of the system being 
investigated, thus overcoming limits of conventional biochemistry or molecular biology tools 
(Villoslada et al., 2009). 
One of the major issues in clinical proteomics studies is the investigation of alterations in protein 
abundance and post-translational modifications eventually related to pathological conditions: the 
development of quantitative proteomics, aimed at the measurement of quantitative changes in the 
protein profile of the biological system under investigation, has stimulated great interest in applying 
proteomics to study mechanisms of diseases and biomarker discovery (Caudle et al., 2010; Alberio 
and Fasano, 2011). 
Technologies used in proteomic research include two-dimensional gel electrophoresis (2-DE), mass 
spectrometry and bioinformatics; a single proteomic technology is not able of resolving all the highly 
analytical difficulty for global identification, quantitation  and characterization of a complex 
proteome, but the combination of separation technologies with mass spectrometry results 
particularly successful in characterizing whole proteome of a chosen system (Alberio and Fasano 
2011;  Rotilio et al., 2012). 
 
 
1.3.1  Gel-based methods 
1.3.1.1  2D-PAGE  
Two-dimensional electrophoresis (2-DE), developed in the 1970s, is the first approach and probably 
still the most frequently used technique to separate complex protein mixtures prior to downstream 
protein characterization by mass spectrometry (Gorg et al., 2004). Complex protein mixtures are 
separated on the basis of the isoelectric points along a pH gradient using isoelectric focusing (first 
dimension) and further of the apparent molecular mass using SDS-PAGE (second dimension) on a 




staining for protein visualization, image analysis is performed using one of the several software 
packages currently available, specifically designed to match protein spots of different gels, compare 
protein patterns and detect protein changes, both qualitative (presence/absence) and quantitative 
(spot intensities). 
2-DE delivers gels that are at the same time an image of protein distribution and levels, and a 
container of separated proteins available for further characterization (Görg et al., 2004). One of the 
main strengths of 2-DE is the ability to visualize protein processing and modification-associated 
isoforms due to post-translational modifications. Specific fluorescent staining facilitates the specific 
detection and identification of relevant PTMs such as glycosylation and phosphorylation of proteins 
separated in 2-DE gels (Jacob and Turck, 2008).  
Nevertheless, there are intrinsic weaknesses in 2-DE. Due to the reduced dynamic range of the 
detection technique, less represented proteins are lost, thus limiting the global characteristic of the 
proteomic approach. Moreover, proteins of extreme hydrophobicity and those of extreme basic or 
acidic pI are not considered in the majority of published studies (Wilkins 2009). To circumvent these 
limitations a number of network enrichment procedures were proposed to complete the list of 
proteins that could have changed in level, but were not observed for intrinsic technical limitations.  
Interestingly, the dynamic range does not differ so much in gel-based and gel-free proteomic 
approaches (Miller et al., 2006; Schulze and Usadel, 2010). Although there is a strong technological 
push towards gel-free techniques, 2-DE continues to be highly preferred for its capacity to resolve 
thousands of spots simultaneously and represents the only technique that can be routinely applied 
for parallel quantitative expression profiling of large sets of complex protein mixtures such as whole-
cell lysates (Görg et al., 2004; Alberio and Fasano, 2011). 
 
1.3.1.2  DIGE 
Differential in-gel electrophoresis (DIGE) permits the simultaneous separation of up to three samples 
on a single gel. In DIGE, samples - usually two samples and one internal standard - are covalently 
labeled with three separate fluorescent dyes, each with a unique excitation/emission wavelength, 
then combined and run together on the same 2D gel (Unlu et al., 1997). Labeling with DIGE 
fluorophors is extremely sensitive, capable to detect as little as 150 pg of a single protein with a 
linear response in protein concentration over five orders of magnitude (Sapra 2009). In addition, this 
method reduces the number of gels needed for an experiment, however the relative high cost of the 





1.3.1.3  Gel staining 
The most commonly employed methods to visualize proteins after 2-DE are Coomassie and silver 
staining, both compatible with downstream mass spectrometric analyses (Shevchenko et al., 1996) 
and whose limits of detection are at picomole and femtomole order, respectively (Miller et al., 2006). 
Silver staining is approximately 100 times more sensitive than Coomassie, but it is lengthy and quite 
laborious, prone to lab-to-lab variability and less reproducible due to the subjective end-point of the 
staining procedure. Moreover it has a narrow linear dynamic range and limits subsequent protein 
analysis by mass spectrometry due to protein cross-linkage (Görg et al., 2004). Colloidal Coomassie 
dispersions (Neuhoff et al., 1988; Candiano et al., 2004) are more sensitive than the classical 
Coomassie stain, but are still less sensitive than the majority of chemical stains employed in 2-DE for 
proteomics (Görg et al., 2004). The development of fluorescent protein dyes with sensitivity 
comparable to silver stain, wide linear dynamic range and compatible with mass spectrometry 
analysis largely improved the comparison of protein amounts in 2-DE gels (Miller et al., 2006). 
Several fluorescent dyes are commercially available, such as Nile red, SYPRO Red, SYPRO Orange and 
SYPRO Tangerine, but the ruthenium-based dye SYPRO Ruby seems the most suitable for proteomic 
applications (Berggren et al., 2000; Rabilloud et al., 2001). Sensitivity is similar to that obtainable with 
silver staining (Berggren et al., 2000; Rabilloud et al., 2001), being the detection limit in the range of 
the femtomole and the linear dynamic range of quantitation of about three orders of magnitude, 
thus overcoming both silver and Coomassie stains in performance. Synthesis and application of the 
metal chelate ruthenium(II) tris(bathophenanthroline disulfonate) (RuBPs), an economic and patent-
free compound, has been described and compared with its commercial analogue SYPRO, 
demonstrating its similar detection limit and dynamic range  (Rabilloud et al., 2001). 
 
1.3.1.4  Protein identification by mass spectrometry 
Upon separation by 2-DE and staining, gel images can be analyzed and spots of interest are cut and 
destained to prevent staining interference with mass spectrometry analysis. Then, the proteins are 
digested within the gel in order to obtain small peptides (up to 20 residues long). Several digestion 
enzymes can be used to this purpose, but trypsin is the most common, as it very specifically cleaves 
proteins at the C-terminal side of lysine and arginine and generates peptides in the preferred mass 
range for subsequent mass spectrometry analysis (about 500 to 4000) (Steen and Mann, 2004; 
Gromova and Celis, 2006). Processed proteins are identified using one of the mass spectrometry 





1.3.2  Gel-free methods 
1.3.2.1  MALDI-TOF 
Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) is a fast and user-friendly mass 
spectometric technique, has good mass accuracy, high resolution and sensitivity. It is widely used in 
proteomics to identify proteins from simple mixtures, as the ones derived either by 2DE or DIGE gel 
spots (Rotilio et al., 2012). In the MALDI ion source samples are co-crystallized with an organic matrix 
on a metal target. A pulsed laser is used to excite the matrix, which causes rapid thermal heating of 
the molecules and eventually desorption of ions into the gas phase. After ionization the samples 
reach the TOF mass analyzer, where ions are separated on the basis of their mass-to-charge (m/z) 
ratios. Ion motion in the mass analyzer can be manipulated by electric or magnetic fields to direct 
ions to a detector, which registers the ion current at each individual m/z value (Balluff et al., 2011). 
Based on this TOF information, a characteristic spectrum is recorded and constitutes a list of peptide 
mass values, that is compared with  those obtained by virtual digestion of all protein sequences in a 
reference database (e.g, Uniprot; see Wieser et al., 2012). 
The main limitations of the MALDI-based PMF approach are: i) it is not reliable for organisms whose 
genomes have not been completely sequenced and annotated; ii) it cannot identify proteins post-
translationally modified, since the peptides generated from these proteins may not match with the 
unmodified protein in the database, iii) it does not work well if several different proteins are present 
in the same spot.  
 
1.3.2.2   LC-MS/MS 
In LC-MS/MS peptides generated from the digestion of complex mixtures of proteins or single spots 
derived by 2DE gels are separated on the basis of hydrophobicity by microscale liquid 
chromatography and introduced into the mass spectrometer, in most of the cases directly via online 
electrospray ionization (ESI). 
During ESI ionization the liquid samples flow through a thin needle at the end of the capillary 
chromatography column and form small drops. Desolvated ions are generated by desorption of 
analyte ions from the droplet surface due to high electrical fields. Peptides are then transferred into 
the mass spectrometer and detected over a wide m/z range; then, single peptide species are isolated 
within the mass spectrometer, usually via a quadrupole mass filter and subjected to collision-induced 
dissociation, resulting in a ladder of peptide fragments, which are detected in a second mass 
spectrum. Peptides’ sequences are blasted in sequence databases (for example PeptideSearch, 
Sequest, Mascot) but only whose having sufficient information to match uniquely to a pre-registered 
peptide sequence (on the basis of the observed and expected fragment ions) contribute to identify 




analyzers, such as quadrupole, ion trap, orbitrap or Fourier transform ion cyclotron resonance 
system, whose accuracy and sensitivity is extremely different (Yates et al., 2009). 
 
1.3.2.3   Stable isotope labeling 
Stable isotope labeling by amino acids in cell culture (SILAC) incorporates isotopic labels into proteins 
via metabolic labeling in the cell culture itself, instead of using covalently linked tags. Cell samples to 
be compared are grown separately in media supplied with either a heavy or light form of an essential 
amino acid, which cannot be synthesized by the cell itself. This makes proteins from the light and 
heavy cells distinguishable and differentially quantifiable by MS (Ong et al., 2002).  
A new quantitative method, isobaric tags for relative and absolute quantitation (iTRAQ), has been 
developed and can be used to profile up to eight different samples (Ross et al., 2004). In contrast to 
the majority of other labeling procedures, iTRAQ relies on quantification at the MS/MS level rather 
than at the MS level. To this purpose, peptides are derivatized with an amine-reactive tagging 
reagent that is available in eight isotope-coded variants, all with an identical molar mass (isobaric). In 
this way, the derivatized peptides are indistinguishable in MS, but exhibit intense low-mass MS/MS 
signature ions that support quantitation. In a comparison of methods for stable isotope labelling and 
DIGE, iTRAQ was reported to be more sensitive for quantitation, but more susceptible to errors in 
precursor ion isolation. (Wuvet al., 2006). 
 
 
1.3.3  Omics discovery of PD biomarkers  
According to FDA, biomarkers are “any characteristic that can be objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes or pharmacological responses to 
therapeutic interventions” (Biomarkers Definitions Working Group, 2001). The definition includes, 
though it is not limited to, the measurement of biochemical components in body fluids and tissues. 
Compared to other areas of clinical interest, biomarker research in PD is still in its early stages of 
both discovery and validation, despite of their need for clinical development of new disease-
modifying therapies and for an optimal patient stratification (Alberio and Fasano, 2011). It has to be 
taken into account the great heterogeneity of PD patients, that requires to enroll a large number of 
patients and of suitable controls, including patients affected by non-PD neurodegenerative disorders 
(Robinson 2010). Moreover, the selection of the appropriate biofluid to search for biomarkers 
appears a fundamental issue (Fasano et al., 2008). 
Several groups attempted to diagnose PD on the basis of the measurement at the peripheral level of 
a single protein or gene transcript, however these proposed tests lacked sufficient sensitivity and 




Recently, a panel of four gene transcripts, selected on the basis of their altered transcription at the 
nigral level, was measured in total blood cells of a large group of sporadic PD patients (n = 105) with 
respect to a smaller group of control subjects (n = 34) (Grunblatt et al., 2010). Although performance 
parameters of this model were good, it is unlikely that genes are differentially expressed both at the 
peripheral and at the central level. Likewise, measurement of α-synuclein, tau and total protein 
concentrations in CSF of patients with PD (n = 51), AD (n = 62), DLB (n = 55), MSA (n = 29) and non-
neurodegenerative neurological disorders (n = 76) allowed Mollenhauer and coworkers to define a 
very accurate predictive model: value of area under the ROC (receiver operating characteristic) curve 
(ROC AUC) is 0.909 for the training set, but in a subsequent validation phase displayed a ROC AUC = 
0.706 for the classification of PD patients (n = 257) and neurological control subjects (n = 47) 
(Mollenhauer et al., 2011). Despite the impressive number of patients and the strong rationale 
behind the search for PD biomarkers in CSF, it appears that the association of a small number of 
targets does not grant a satisfactory performance when a cross-validation is performed. Eventually, 
one must consider the discomfort for the patient to undergo a CSF sampling. 
Unbiased discovery studies that use proteomic or metabolomic techniques have the great advantage 
to identify a larger panel of targets to be included in the predictive model, and to explore a greater 
universe of candidates without limiting to those that have been related to pathogenesis, as it is the 
case with the metabolomic profiling of plasma proposed by Bogdanov correctly classified PD patients 
(n = 66) and control subjects (n = 25) in a cross-validation procedure by permutation test (Bogdanov 
et al., 2008). 
As a whole, a general procedure can be put forward for the outcome of a biomarker discovery 
project: (i) a suitable model should be proposed on the basis of a strong rationale, as a biomarker 
discovery strategy; (ii) subject enrolment conditions should be set on the basis of the given rationale; 
(iii) proteins that are significantly correlated with the conditions set at point (ii) need to be 
unambiguously identified; (iv) a new set of biomarker candidates coming up from this approach 
should be independently confirmed; (vi) eventually, the cohort of subjects should be re-evaluated by 
means of conventional (biochemical) methods to deepen findings that emerged by the unbiased 







Fig. 3: Ideal flowchart of an hypothesis-generating proteomic investigation, 
starting from the design of a suitable model for a biomarker discovery 
strategy, leading to the identification of the involved panel of protein, to end 
with the confirmation of the new hypothesis by a focused validation. 





























Diagnosis of PD is currently based on clinical manifestations of the disease. The great interest in 
biomarker discovery for PD is due to their need for early diagnosis and clinical development of new 
disease-modifying therapies.    
(T)-Lymphocytes express some features of the dopaminergic system, so in PD patients they could 
carry some protein alterations peculiar of dopaminergic cells. In particular, patients affected by 
familial forms of PD (about 20% of all PD cases) may express, also at the peripheral level, alterations 
that mirror the pathogenic process at the central level.  
We decided to investigate this possibility through un unbiased approach, detecting differences in T 
cells proteome from PD patients and control subjects; we enriched PD patients’ group with Early 
Onset PD patients, who have a greater probability to be affected by a genetic form of the disease, in 
order to highlight possible effects due to the genetic background. Protein expression’s differences 
between PD patients and control subjects’ groups will be evaluated using two-dimensional 
electrophoresis (2-DE). 
Once significant differences will be found, a function taking into account contributes of changing 
proteins will be calculated in order to rightly predict PD patients and controls. 
Our aim is also to identify proteins correlating with other parameters of disease: duration, gravity of 
symptoms, age at onset. This will confirm that T-lymphocyte proteome changes are a valid tool to 
correctly classify PD patients and to follow progression of the disease from a peripheral system. 
This is the discovery phase of a  broader study of biomarker identification for PD. Results shown in 
this thesis will be validated in a subsequent project in which proteome changes of PD patients’ T cells 
will be confirmed in a larger cohort of subjects through a different technique.  
Furthermore, as we consider T cells as dopaminergic circulating cells, we suppose that long term 
dopaminergic therapy daily assumed by PD patients could induce changes in T cells proteome, so also 




























Patients and control subjects were enrolled by the Parkinson’s Disease Center at the Department of 
Neuroscience, University of Torino, and by the Neurology Division at the Department of Translational 
Medicine, University of Eastern Piedmont. Every subject was associated to an alphanumeric code to 
ensure that his/her identity was not disclosed to investigators. 
For biomarker discovery, 32 subjects were recruited. Among them, 15 subjects were PD patients, 
varied in terms of age, age at onset, pharmacological treatment and familiarity. This population was 
intentionally enriched in early-onset patients (eight of 15) to highlight possible effects due to the 
genetic background. In particular, we classified as Early Onset PD patients (EOPD) those patients that 
had onset of the disease before age 45. Similarly, we recruited 17 control subjects. This cohort 
included also three patients affected by atypical degenerative parkinsonisms. Table 3 reports 
demographic and clinical data for enrolled subjects. A cohort of 17 patients (partially overlapping 
with those of the previous recruitment) were enrolled by the same Centers to evaluate the effect of 
dopaminergic therapies and their data are listed in Table 4. 
The summary of demographic and clinical data for all enrolled subjects are reported in Table 5. 
Gender and age distributions were similar in different groups. Absolute inclusion criteria for PD 
patients were: idiopathic PD, absence of atypical signs and a good response to L-DOPA. Supportive 
criteria were: asymmetry of symptoms or signs at onset, clinical course of more than five years 
without atypical signs, L-DOPA induced motor fluctuations or dyskinesias. Exclusion criteria for 
patients and control subjects were: use of neuroleptic drugs, focal cerebral lesions and a history of 
encephalitis (Jancovic 2008; Litvan et al., 2003; Litvan et al., 1996; Gilman et al., 2008). Subjects 
suffering from inflammatory or infectious diseases and subjects that took drugs capable of 
interfering with T-lymphocytes at the time of enrollment were excluded from the study. All patients 
signed an informed consent before being recruited for the present study, according to the guidelines 






Table 3: Demographic and clinical data of subjects enrolled for the part of biomarker discovery. The 
code contains specification of each subject: CTM stands for Male Control Subject, CTF for 
Female Control Subject, LOM and LOF for Male and Female Late Onset PD patient, 
respectively, EOM and EOF for Male and Female Early Onset PD patient, respectively, and 















CTF_NO021 F 63 n.a. 0 0 No 0 
CTF_TO035 F 68 n.a. 0 0 No 0 
CTF_TO027 F 63 n.a. 0 0 No 0 
CTF_TO033 F 63 n.a. 0 0 Yes 0 
APF_TO047 F 73 59 0 0 No 0 
APM_NO015 M 70 64 600 0 No 0 
CTM_TO059 M 44 n.a. 0 0 No 0 
CTF_TO063 F 59 n.a. 0 0 No 0 
CTF_TO065 F 55 n.a. 0 0 No 0 
CTF_TO043 F 65 n.a. 0 0 No 0 
CTM_NO022 M 51 n.a. 0 0 No 0 
APF_TO042 F 79 75 600 0 No 0 
CTM_NO027 M 64 n.a. 0 0 No 0 
CTM_TO058 M 43 n.a. 0 0 No 0 
CTM_TO051 M 60 n.a. 0 0 No 0 
CTF_TO060 F 47 n.a. 0 0 No 0 
CTM_TO054 M 51 n.a. 0 0 No 0 
EOM_NO017 M 50 47 400 1 No 1 
EOF_TO048 F 43 32 900 0 Yes 2 
EOM_NO018 M 43 36 300 1 No 4 
EOM_TO049 M 55 43 500 0 No 3 
EOM_TO008 M 47 39 500 1 No 2.5 
EOM_TO022 M 39 37 0 0 No 1 
EOF_TO050 F 57 45 450 0 Yes 2 
EOM_NO028 M 48 42 150 1 No 2.5 
LOM_TO040 M 68 67 0 0 Yes 1 
LOF_TO021 F 64 63 0 1 Yes 2 
LOF_TO016 F 58 52 400 1 No 1.5 
LOM_TO006 M 65 52 1200 1 No 3 
LOM_TO064 M 67 63 400 1 Yes 1 
LOF_NO023 F 56 52 0 0 Yes 1 
LOM_TO066 M 58 54 400 1 No 2 


























1 F 43 32 11 900 0 2 
2 M 55 43 12 500 0 3 
3 M 39 37 2 0 0 1 
4 F 57 45 12 450 0 2 
5 F 46 36 10 600 0 2 
6 M 68 67 1 0 0 1 
7 F 56 52 4 0 0 1 
8 M 43 36 7 300 Rotigotine (16) 4 
9 M 47 39 8 500 Ropinirole (8) 2.5 
10 M 48 42 6 150 Ropinirole (20) 2.5 
11 F 64 63 1 0 Pramipexole (2.1) 2 
12 F 58 52 6 400 Rotigotine (4) 1.5 
13 M 65 52 13 1200 Ropinirole (16) 3 
14 M 67 63 4 400 Pramipexole (1.05) 1 
15 M 58 54 4 400 Pramipexole (2.1) 2 
16 M 62 46 16 450 Pramipexole (2.1) 2.5 




Table 5: Summary of demographic and clinical data for all enrolled subjects. 
 Biomarkers Discovery Effect of DA therapy 
 PD patients (n = 15) Controls (n = 17) PD Patients (n = 17) 
Age ± SD (years) 54.5 ± 9.2 59.9 ± 10.2 54.5 ± 9.1 
Male % 67 41 65 
PD duration ± SD (years) 6 ± 4  7 ± 5 
Medications    
Unmedicated 3 - 3 
L-DOPA 3 2 4 
DA agonists 1 0 1 





3.2  T-lymphocyte isolation  
All subjects underwent a venous blood sampling (20 ml) from the antecubital vein, between 9 and 10 
a.m., after an overnight fast. Whole blood was collected into vacuum tubes containing EDTA, diluted 
with 50 ml of phosphate-buffered saline (PBS) and stratified in two 50 ml tubes on top of 15 ml of 
Lympholyte®-H (Cedarlane) each. After centrifugation (800×g, 20 min, 20°C) peripheral blood 
mononuclear cells (PBMC) were removed and pelleted through centrifugation (400×g, 15 min, 20°C). 
Pellets were washed twice with 10 ml of magnetic-activated cell sorting (MACS) buffer (Miltenyi 
Biotec). The isolation of T lymphocytes was achieved by MACS with the Pan T-cell isolation kit 
(Miltenyi Biotec) using the manufacturer’s protocol.  
 
 
3.3  Two-dimensional electrophoresis and image analysis 
T-lymphocytes were resuspended in 120 µl UTC (7 M urea, 2 M thiourea and 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)) with a protease inhibitors cocktail 
(Sigma-Aldrich). Cells were left in this solution for 30 min to allow a complete cell lysis, sonicated 
(3×5 sec) and centrifuged (12000×g, 20 min, 10°C) to precipitate the cellular debris. Protein 
concentration in the extracts was determined Bradford assay (Serva). Total proteins (200 μg) were 
separated through two-dimensional electrophoresis (2-DE) using 18 cm IPG DryStrips with a 
nonlinear 3–10 pH gradient (GE Healthcare) followed by 14% SDS-PAGE. The resulting maps were 
stained with Ru(II) tris(bathophenanthroline disulfonate) (Serva). Images were acquired (12 bit 
grayscale) with the GelDoc-It Imaging System (UVP) and analyzed with ImageMaster 2D Platinum (GE 
Healthcare); spots showing significant variation among subject groups (Wilcoxon test, p<0.05) were 
excised from gels and the corresponding proteins identified by LC-MS/MS fragmentation.  
 
 
3.4  Statistical analysis  
Spot volumes were normalized by the total volume of a subset of spots common to all gels. Spots 
that were missing in more than 25% of gels were not taken into account. Missing spot values in less 
than 25% of gels were replaced by the mean value of the spot volume of the group or, if the mean 
was lower than the 98th percentile, by the minimum value observed in the group (Albrecht et al., 
2010).  
Relative volumes were analyzed by the non-parametric Wilcoxon test to find significant differences in 
patients with PD with respect to control subjects, in early-onset patients with respect to late-onset 




significant differences (p < 0.05)  in patients administered with dopamine agonists with respect to 
patients not treated with dopamine were excluded by the subsequent analysis for biomarker 
discovery.  
The Pearson linear correlation coefficient r was evaluated according to Eq. 1, where x is the 
independent variable (i.e., Hoehn and Yahr score, age, years from onset, daily L-DOPA dose), y is the 
relative spot volume,  x   is the mean x value, y  is the mean y value, xy is the  x·y  product, xy is the 
product of x  and y   mean values (Surinova et al.,  2011).  
 
  
  (1) 
 
 
Spots showing linear correlation with age and daily L-DOPA dose were excluded by the subsequent 
analysis for biomarker discovery.  
Predictive models for the classification of PD patients with respect to control subjects and of early-
onset patients with respect to late-onset were built by linear discriminant analysis (LDA) of the spots 
identified as described above (McDonald 2009). In this case, missing values were set to half of the 
minimum value observed in the gel. A likelihood score was assigned to each subject by linear 




Simplified models were obtained by progressively removing groups of spots in terms of their 




where ci is the LDA coefficient for spot i and  PDiCOi VolVol ,,   is the absolute separation of the 
mean values of spot i in control subjects (CO) and PD. Each predictive model has been tested with 
the leave-one-out method (McDonald 2009). The performance of predictive models has been 
quantified by measuring the area under the ROC curve.  
Aggregative nesting of spots included in the predictive model was based on pairwise Pearson 
correlation (Eq. 1), where x and y are relative spot volumes. 



























   
(4)   
 
 
where σCO and σPD are standard deviations of relative spot volumes in CO and PD groups, NCO and NPD 
are numbers of subjects in the groups, and μCO and μPD are mean values of relative spot volumes in 
the groups (McDonald 2009). 
The minimum number of subjects needed to reach statistical significance for the part “Dopaminergic 
therapies modulate T cell proteome of PD patients” was calculated in analogy to Eq. 4, according to 





where σDago- and σDago+  are standard deviations of relative spot volumes in groups of patients not 
assuming (Dago-) or assuming (Dago+) dopamine agonists; NDago- and NDago+ are numbers of patients 
in each group; and μDago- and μDago+  are mean values of relative spot volumes in each group.  
All procedures for data analysis and graphics were written in R, an open-source environment for 
statistical computing (R Development Core Team, 2009). 
 
 
3.5  In-gel digestion, mass spectrometry and protein identification  
Spots were manually excised and destained (50% ethanol), dehydrated with acetonitrile (2 × 20 min 
100 µl) and then dried at 37°C by vacuum centrifugation. The gel pieces were then swollen in 10 µl 
digestion buffer containing 50 mM NH4HCO3 and 12.5 ng/µl modified porcine trypsin (sequencing 
grade, Promega). After 10 min, 30 µl of 50 mM NH4HCO3 were added to the gel pieces and digestion 
allowed to proceed at 37°C overnight. The supernatants were collected and peptides were extracted 
in an ultrasonic bath for 10 min (twice 100 µl 50% acetonitrile, 50% H2O, 1% formic acid; twice 50 µl 
acetonitrile). All the supernatants were collected in the same tube, dried by vacuum centrifugation 
and dissolved in 5 µl 2% acetonitrile, 0.1% formic acid in water. 
Peptides from each sample were then separated by reversed phase nano-HPLC-Chip technology 
(Agilent Technologies) online-coupled with a 3D ion trap mass spectrometer (model Esquire 6000, 
Bruker Daltonics) installed at the Department of Biotechnology, University of Verona. The chip was 
composed of a Zorbax 300SB-C18 (43mm×75µm, with a 5µm particle size) analytical column and a 
Zorbax 300SB-C18 (40 nL, 5µm) enrichment column. The complete system was fully controlled by 






















































ChemStation (Agilent Technologies) and EsquireControl (Bruker Daltonics) softwares. The scan range 
used was from 300 to 1800 m/z. For tandem MS experiments, the system was operated with 
automatic switching between MS and MS/MS modes. The three most abundant peptides of each m/z 
were selected to be further isolated and fragmented. The MS/MS scanning was performed in the 
normal resolution mode at a scan rate of 13000 m/z per second. A total of five scans were averaged 
to obtain an MS/MS spectrum. Protein identification was manually performed by searching the 
National Center for Biotechnology Information non-redundant database using the Mascot 2.3 MS/MS 
Ion Search program (http://www.matrixscience.com). The following parameters were set: specific 
trypsin digestion, up to one missed cleavage; complete carbamidomethylation of cysteines, partial 
oxidation of methionines, partial protein N-terminal acetylation, peptide mass tolerance ± 0.9 Da, 
fragment mass tolerance ± 0.9 Da, 1+ to 3+ peptide charge, species restriction to human. All 
identified proteins had a Mascot score corresponding to a statistically significant (p < 0.05) confident 
identification according to Fisher's test. At least 2 different peptides had to be assigned. Peptide and 
protein identifications corresponding to keratins or trypsin were not taken into account. 
Double assignments were refined by matching spots with reference 2-DE maps available in the swiss-
2Dpage database (http://world-2dpage.expasy.org/swiss-2dpage/). In particular, we referred to the 
LYMPHOCYTE_HUMAN map for disambiguation. In the case the ambiguous assignment was not 
resolved by matching, we checked the correct assignment by western blotting. 
 
 
3.6  Quantitative Western blotting analysis  
For one-dimensional Western blotting, cell lysates (20 µg) were denatured in Laemmli sample buffer 
for 5 min at 98°C and electrophoresed on 10% SDS-PAGE gel. 2-DE was performed as described 
above. Gels were transferred to polyvinylidene difluoride (PVDF) membranes at 1mA/cm2, 1.5 h 
(TE77pwr, Hoefer). Membranes were saturated in 5% non-fat milk in TBS-T (0.1 M Tris-HCl pH 7.4, 1.5 
M NaCl and 0.5% Tween-20) and incubated in the same buffer at 4°C overnight with the following 
primary antibodies: 
- goat anti-fibrinogen polyclonal antibody (Abnova), 1:10000 dilution, or 
- mouse anti-transaldolase polyclonal antibody (Abcam), 1:500 dilution, or  
- mouse antiperoxiredoxin 6 monoclonal antibody (Abnova), 1:5000 dilution, or 
- mouse antiprolidase polyclonal antibody (Abnova), 1:1000 dilution, or 
- mouse anti-beta actin monoclonal antibody (GeneTex), 1:3000 dilution, or 
- mouse anti-alpha tubulin monoclonal antibody (Sigma), 1:10000 dilution, or 
- goat anti-serpin B9 polyclonal antibody (Abcam), 1:2000 dilution, or 




Membranes were then washed with TBS-T and incubated with secondary peroxidase-conjugated 
antibody in 5% milk-TBS-T (anti-goat-IgG antibody, Millipore, 1:8000, or anti-mouse-IgG antibody, 
Upstate, 1:3000) for chemiluminescence detection (Millipore). Photographic films were scanned with 
a Epson Perfection V750 Pro transmission scanner (Epson) and images (16 bit grayscale) were 
analyzed using ImageJ software (http://rsb.info.nih.gov/ij/). Images showing dynamic range 
saturation were discarded. Signal intensities were corrected for protein loading by normalization to 
beta actin intensity. 
 
 
3.7  Cell culture  
The human liver carcinoma Hep G2 cell line was maintained at 37°C in a 5% CO2 humidified 
atmosphere in RPMI 1640, supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 
μg/ml streptomycin, and 2 mM L-glutamine. Stock flasks were transferred for culture twice weekly or 
as required to maintain optimal cell growth.  
The Jurkat T-cell leukemia cell line was maintained at 37°C in a 5% CO2 humidified atmosphere in 
RPMI 1640, supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 2 mM L-glutamine. Stock flasks were transferred for culture twice weekly or as 
required to maintain optimal cell growth. When flasks were filled, cells were collected by 
centrifugation, lysed with 120 μl RIPA buffer (25 mM Tris-HCl pH 7.4, 0.15 M NaCl, 0.1% SDS, 1% 
Triton X-100, 1% sodium deoxycholate) and centrifuged (13000 g, 30 min, 10 °C). Proteins were 




3.8  RNA extraction, retrotranscription and PCR  
RNA was extracted from T lymphocytes and PBMC of the same control subject and from HepG2 cells 
using NucleoSpin RNA II (Macherey-Nagel) following manufacturer’s instructions and treated with 
recombinant DNase (Promega) in order to remove genomic DNA. One microgram of RNA was reverse 
transcribed into first-strand cDNA in a 20 μl final volume using the Maxima™ First Strand cDNA 
Synthesis Kit (Fermentas). PCR was performed by Thermocycler One Personal (Euroclone).  
The expression of beta fibrinogen (FGB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
housekeeping gene was evaluated using primers reported in Table 6. Optimal PCR conditions were 
identified for each primer pair. Reactions were incubated at 95°C for 3 min, then 35 cycles of 95°C for 








3.9  Primer design  
Primer design was performed by using Primer3 software (http://primer3.sourceforge.net/) and 
manually adjusted if needed. Primer pairs were designed to avoid the amplification of undesired 
sequences that share high identity degree and the amplification of common sequences among the 
splicing variants of the same transcript. Moreover, primers were designed to have comparable 
melting temperature and reaction efficiency. Primer specificity was tested by BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and experimentally by the positive control amplification. 
 
Table 6: sequences of specific primers: F = forward primer; R = reverse primer. 
Gene Primer Sequence Amplicon size (bp) 
FGB F TGGCAAAAGAGGCAGAAGCAAG 
145 
FGB R CCAGGATTGAACGAAGCACACG 
GAPDH F GAGTCAACGGATTTGGTCGT 
238 




3.10  Separation of membrane proteins 
Freshly isolated T lymphocytes and PBMC from the same subjects were treated for separation of cell 
surface protein. The separation was achieved through biotinylation of whole cells with the Pierce Cell 
Surface Protein Isolation Kit (Thermo Fisher Scientific). 
After the separation, cell surface proteins and internal proteins were loaded on SDS-PAGE and 

















4.1  Two-dimensional electrophoresis profiling of T-cell proteins 
Human T-cell protein expression profiles of PD patients and control subjects were obtained through 
2-DE; a representative map from subject CTF_NO021 is showed in Fig. 4. A total of about 250 spots 




Fig. 4: illustrative map of T-cell protein expression profile obtained by 2-DE. 
 
The 32 maps were screened to identify at first proteins or protein modifications whose changes were 
linked to confounding factors such as therapy and age. Spots showing linear Pearson correlation with 
age (evaluated in control subjects only) or daily L-DOPA dose, or showing significant differences 
between patients treated or not with dopamine agonists (Wilcoxon test, p<0.05) were excluded from 
the further analysis. By comparing 2-DE maps from 15 PD patients to 17 control subjects, we selected 
20 protein spots showing significantly different levels in the two groups (Wilcoxon test, p<0.05). The 
distribution of fold of change values (in Log2 scale) of patients vs. control subjects and of Wilcoxon 




Proteins corresponding to selected spots were identified by LC-MS/MS; identities of these 20 
proteins and fold of induction in the two groups are reported in Table 7. Additional information 
about details on protein identification by mass spectrometry are listed in Table 15, at the end of this 
chapter. 
Fig. 5: For each of the 20 spots showing significantly different levels in PD 
patients and control subjects, the fold of change in Log2 scale (A) and the 




Fig. 6: position in the 2-DE map of the 20 proteins showing different levels in 






Table 7: Identification of protein spots that are significantly different in PD patients. 
Spot No. Protein Uniprot Id Correlation p (Wilcoxon test) 
86 Vinculin P18206 ↓ PD 0.003 
87 Vinculin P18206 ↓ PD 0.018 
329 Vimentin P08670 ↑ PD 0.006 
335 Talin-1 Q9Y490 ↓ PD 0.016 
362 Beta-fibrinogen P02675 ↓ PD 0.005 
365 Beta-fibrinogen P02675 ↓ PD 0.003 
368 Beta-fibrinogen P02675 ↓ PD 0.014 
369 Beta-fibrinogen P02675 ↓ PD <0.001 




P33241 ↑ PD 0.025 
414 Septin-6 Q14141 ↑ PD 0.047 
591 Vimentin P08670 ↑ PD 0.003 
598 Moesin P26038 ↑ PD 0.012 
657 Gelsolin P06396 ↓ PD 0.023 
676 Transaldolase P37837 ↑ PD 0.007 
679 Transaldolase P37837 ↑ PD 0.014 
842 Twinfilin-2 Q6IBS0 ↑ PD 0.034 
871 
Rho GDP dissociation 
inhibitor isoform 2 
P52566 ↑ PD 0.031 
1639 Beta actin fragment P60709 ↓ PD 0.030 






4.2  Correlation of selected spot volumes with Hoehn and Yahr 
score and disease duration 
The occurrence of linear correlation of selected spot volumes (spots changing in PD patients and 
control subjects) with the Hoehn and Yahr score (H&Y score) and the duration of the disease, was 
evaluated in order to test if some of the proposed biomarkers changed with time or disease severity. 
Correlation with the Hoehn and Yahr score was observed for 8 spots, listed with their corresponding 
identities in Table 8. These spot volumes were linearly combined to afford a function that 
significantly tracks the Hoehn and Yahr score. Multiple regression on PD patients allowed us to 
determine a set of coefficients for the eight spots listed above (Table 8). In this way, the spot volume 
combination linearly correlates with the Hoehn and Yahr score (r = 0.674, p = 0.006) (Fig. 7A). The 
significance of the correlation is improved by adding control subjects at x = 0 (r = 0.603, p < 0.0005) 
(Fig. 7B).  
 
Table 8: Coefficients for linear combinations of spots to build a function that tracks disease severity 
(H&Y score) and duration (Years from onset). 





86 Vinculin 21.5  
362 Beta-fibrinogen 112  
365 Beta-fibrinogen -52.4  
368 Beta-fibrinogen 36.7  
369 Beta-fibrinogen -7.09 53.5 
405 Lymphocyte-specific Protein 1 60.5  
591 Vimentin  76.6 
598 Moesin -38.2 158 







Fig. 7: Predictors of PD progression. A linear combination of eight spots 
correlates linearly with the Hoehn and Yahr score. Linear correlation is 
significant both excluding (A) and including (B) control subjects. 
 
 
Correlation with the duration of the disease, measured in years from onset, was observed for 4 spots 
(Table 8). These spot volumes were linearly combined to afford a function that significantly tracks 
disease duration. Multiple regression on PD patients allowed us to determine a set of coefficients for 
the four spots listed above (Table 8). In this way, the spot volume combination linearly correlates 
with the disease duration (r = 0.516, p = 0.049) (Fig. 8A). The correlation is improved by adding 
control subjects at x = 0 (r = 0.548, p = 0.001) (Fig. 8B). Worth of note, spots 369, 598 and 1641 
correlate with both parameters (score H&Y and disease duration). 
 
 
Fig. 8: Predictors of PD progression. A linear combination of eight spots 
correlates linearly with the disease duration. Linear correlation is significant 
both excluding (A) and including (B) control subjects. 
 
 
Pearson correlation analysis of single spots with the disease stage (Score H&Y) and disease duration 






Fig. 9: Pearson correlation analysis of spots 86 (vinculin), 362 (vinculin), 365 
(β-fibrinogen), 368 (β-fibrinogen), 369 (β-fibrinogen), 405 (lymphocyte-
specific protein 1), 598 (moesin) and 1641 (14-3-3 epsilon) with the disease 
stage, expressed as Hoehn and Yahr score. Correlation coefficients are 





Fig. 10. Pearson correlation analysis of spots 369 (β-fibrinogen), 591 
(vimentin), 598 (moesin) and 1641 (14-3-3 epsilon) with the disease duration, 
expressed as years from onset. Correlation coefficients are calculated 
according to Eq. 1. 
 
 
4.3  Linear discriminant analysis of selected spot levels  
We analyzed all spots (n = 20) showing significantly different levels in PD patients by LDA so to obtain 
a likelihood score (PD Score) expressed as a linear combination of relative spot volumes (linear 
coefficient and weights of each spot are reported in Table 10). Spot combinations were significantly 
different in PD patients with respect to control subjects (Wilcoxon test, p < 10-8, Fig 11A), with a 
cutoff value of 0.67. To effectively test the performance of the model, each subject was iteratively 
excluded by the training set and predicted on the basis of the other subjects. According to the "leave-
one-out" procedure (Mc Donald 2009) we obtained 87% sensitivity and 81% specificity. Predictions 










Fig. 11: Scoring functions built on set of 20 spots yield the PD likelihood. 
Classifiers obtained by the leave-one-out cross-validation have been used to 
build ROC curve. 
 
A simplification of the model was achieved by ranking the 20 spots in terms of their ability to 
discriminate PD patients from control subjects. Thus, the six spots showing the worst contribution 
(weight < 0.3, Table 10) were discarded and the LDA was performed on the remaining 14 spots. PD 
Scores were significantly different in PD patients with respect to control subjects (Wilcoxon test, p < 
10-8, fig 12A), with a cutoff value of -0.31. In this case, the "leave-one-out" cross-validation procedure 
of the model allowed us to obtain 100% sensitivity and 94% specificity. Predictions obtained so far 
were used to build a ROC curve with an area under curve of 0.996 (Fig. 12B).  
 
Fig. 12: Scoring functions built on set of 14 spots yield the PD likelihood. 
Classifiers obtained by the leave-one-out cross-validation have been used to 
build ROC curve.  
 
 
We further simplified the model by removing spots with weight < 1, thus obtaining a 9-spot model 




subjects (Wilcoxon test, p < 10-8, Fig 13A), with a cutoff value of -2.90. The "leave-one-out" cross-
validation procedure of the model allowed us to obtain 100% sensitivity and 88% specificity, and the 
ROC curve built with these predictions had an area under curve of 0.992 (Fig. 13B). 
 
Fig. 13: Scoring functions built on set of 9 spots yield the PD likelihood. 
Classifiers obtained by the leave-one-out cross-validation have been used to 
build ROC curve.  
 
 
For comparison, results of the three proposed predictive models are summarized in Table 9. 
 
 
Table 9: Summary of performance parameters for the three predictive models. Cutoff values are 
expressed in terms of the likelihood PD score obtained as a linear combination of selected 
spot relative volumes; ROC = receiver operating characteristic; AUC = area under curve; p 
values refer to Wilcoxon test on PD scores. Sensitivity, specificity and ROC AUC were 
obtained by leave-one-out cross-validation. 
 20-spot model 14-spot model 9-spot model 
Cutoff 0.67 -0.31 -2.90 
Sensitivity (%) 87 100 100 
Specificity (%) 81 94 88 
ROC AUC 0.906 0.996 0.992 









20-spot model 14-spot model 9-spot model 
Coefficient Weight Coefficient Weight Coefficient Weight 
86 Vinculin -600.7 1.742 -497.3 1.442 -320.2 0.9286 
87 Vinculin -264.4 1.369 -267.3 1.384 -289.3 1.498 
329 Vimentin 10.37 0.2096 - - - - 
335 Talin-1 215.5 1.203 233.0 1.300 148.8 0.8304 
362 Beta-fibrinogen 636.0 3.296 525.1 2.722 401.0 2.078 
365 Beta-fibrinogen 83.49 2.182 68.00 1.777 91.44 2.389 
368 Beta-fibrinogen 248.5 1.939 267.9 2.090 192.6 1.503 
369 Beta-fibrinogen -237.4 6.758 -232.9 6.630 -217.2 6.184 




116.0 0.6441 109.0 0.6048 - - 
414 Septin-6 95.30 0.1718 - - - - 
591 Vimentin -32.40 0.4060 -30.29 0.3796 - - 
598 Moesin 68.17 0.3576 77.40 0.4060 - - 
657 Gelsolin -276. 7 1.058 -326. 1 1.247 -281.2 1.075 
676 Transaldolase 288.6 0.5737 249.38 0.4958 - - 
679 Transaldolase -93.18 0.1289 - - - - 
842 Twinfilin-2 7.034 0.01180 - - - - 
871 
Rho GDP dissociation 
inhibitor isoform 2 
9.525 0.1493 - - - - 
1639 beta actin fragment -1.948 0.02010 - - - - 
1641 14-3-3 epsilon -87.95 0.3231 17.97 0.06600 - - 
 
 
A comparison of ROC curves of the three models is showed in Fig. 14; the prediction of single 
subjects through the procedure described above and performance’s parameters for the three models 






Fig. 14: ROC curves of the three models 
obtained by the leave-one-out cross-validation. 
Open circles are for the 20-spot model; filled 






Fig. 15: prediction of single subjects and performance parameters for the 20-spots 
model (A), the 14-spots model (B) and the 9-spots model(C). The bars represent 
the predicted probability of a subject to be a control (green), or a PD patient (EOPD 
are red bars, LOPD are blue bars, respectively), calculated with the scoring function 
obtained with the other 32 subjects. The true identity of each subject is indicated 






To test the power of our analysis we evaluated the intra-group variance and the difference of mean 
values for each spot included in the three models (Eq. 4). The minimum number of subjects required 
for a significant verification is in the range from 10 to 30 for most spots (Table 11).  
 
Table 11: Power analysis of the 20 spots showing the minimum number of subjects to be included in 
validation studies. 
Spot No. Number of subjects Spot No. Number of subjects 
86 3 414 13 
87 6 591 19 
329 8 598 12 
335 9 657 10 
362 5 676 4 
365 3 679 32 
368 4 842 14 
369 2 871 8 
382 6 1639 >100 




4.4  Linear discriminant analysis of spots showing differences 
between late-onset and early-onset patients 
To test the possibility to discriminate PD subtypes, we compared LO PD patients to EO PD patients 
(Fig. 16). We selected 7 protein spots (Wilcoxon test, p < 0.05) and identified them by LC-MS/MS 
(Table 12; see Table 15 for mass spectrometry details). We performed a LDA on selected spots in LO 
patients with respect to EO patients so to obtain a likelihood score (LO vs. EO Score) expressed as a 
linear combination of relative spot volumes (Table 12).  





Fig. 16: 7 spots discriminate late-onset (LO) from early-onset (EO) patients. 
For each of the 7 spots, the fold of change in Log2 scale (A) and the Wilcoxon 
test p value (B) are reported. 
 
 
Table 12: LOPD patients vs. EOPD patients: Identification, fold of change and p value of Wilcoxon test. 
Coefficients and weights refer to the LDA refinement procedure described in the text. 
Spot No. Protein Uniprot Id Correlation p Coefficient Weight 
351 Beta tubulin P07437 ↑ LOPD 0.047 100.4 2.081 
363 
Protein disulfide isomerase 
A3 
P30101 ↑ LOPD 0.013 33.97 0.5704 
392 Vimentin P08670 ↓ LOPD 0.046 41.20 1.279 




P00491 ↑ LOPD 0.013 467.5 2.894 
940 Glutathione S-transferase P P09211 ↑ LOPD 0.016 -22.84 0.2074 
1787 PDCD6 interacting protein Q8WUM4 ↑ LOPD 0.047 559.0 1.144 
 
Spot combinations were significantly different in LO PD patients with respect to EO PD patients 
(Wilcoxon test, p = 0.006, Fig 17B), with a cutoff value of 11.0. To effectively test the performance of 
the model, we performed the "leave-one-out" procedure described above and obtained 71% 
sensitivity and 100% specificity. Predictions obtained so far were used to build a ROC curve with an 









   
 Fig. 17: Panel A: position in the 2-DE map of the 7 proteins showing different 
levels in EOPD respect to LOPD. Panel B and C: definition of a clinical subtype 
predictive model by linear discriminant analysis. The scoring function yields 
LO vs. EO classification scores (B) and the ROC curve obtained by the leave-
one-out cross-validation (C). 
Panel D: prediction of single patients. The bars represent the predicted 
probability of a patient to be a EOPD patient (red), or a LOPD patient (blue), 
calculated with the scoring function obtained with the other 14 subjects. The 
true identity of each subject is indicated in its code and refers to codes 







4.5  Dopaminergic therapies modulate T cell proteome of PD 
patients  
To evaluate the possible effect of dopaminergic therapy on T-lymphocyte proteome, relative 
volumes of spots from the 2-DE maps were analyzed by the non-parametric Wilcoxon test to find 
significant differences in patients with PD treated or not with dopamine agonists (Ropinirole, 
Pramipexole or Rotigotine). Seven spots were found to vary significantly as a function of the 
treatment with dopamine agonists: they were identified by LC/MS-MS as prolidase, actin-related 
protein 2, F-actin capping protein subunit beta, tropomyosin alpha-3 chain, proteasome activator 
complex subunit 1, peroxiredoxin 6 and an isoform of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). Fig 18 summarize the changes in terms of box-and-whiskers plots. 
 
 
Fig. 18: Box-and-whiskers plots of spots whose relative volume is significantly 
different in patients under DA agonist therapy (1) with respect to patients 




The occurrence of any correlation between spot levels and daily L-DOPA dose was evaluated by 
Pearson’s linear correlation [Eq. (1)]. Among the detected spots, two of them (ATP synthase subunit 
beta and proteasome subunit beta type-2) displayed a significant linear correlation with the dose of 






Fig. 19: linear correlation of spot 441 and spot 963 relative volumes to the L-
DOPA daily dose (mg). p Values refer to Pearson’s correlation analysis. The 
Pearson correlation coefficient and the slope of the straight line are indicated  
below the graphs. 
 
 
Identification by LC/MS-MS of proteins correlating with dopaminergic therapy are reported in Table 
13, while their position in a representative 2-DE map is showed in Fig. 20. Mass spectrometry 
identification details are reported Table 15. 
 
 




Protein name Uniprot ID Correlation P* 
400 Prolidase P12955 Dagoa ↑ 0.014 
441 
ATP synthase subunit beta, 
mitochondrial 
P06576 L-DOPA ↑ 0.029 
608 Actin-related protein 2 P61160 Dago ↑ 0.025 
774 
F-actin-capping protein subunit 
beta 
P47756 Dago ↑ 0.042 
779 Tropomyosin alpha-3 chain P06753 Dago ↓ 0.004 
839 
Proteasome activator complex 
subunit 1 
Q06323 Dago ↑ 0.033 




P04406 Dago ↓ 0.014 
963 Proteasome subunit beta type-2 P49721 L-DOPA ↓ 0.003 
*for protein correlating with dopamine agonist therapy, p values refer to the Wilcoxon test. For spots showing linear 






Fig. 20: Position in the 2-DE map of the proteins showing different levels in 
relation to dopaminergic therapy.  
Spots labeled in white are observed to change in patients under dopamine 
agonist therapy, whereas spots in black are correlated to L-DOPA daily dose. 
 
The minimum number of subjects required to obtain statistical significance of changes, calculated 
according to Eq. 5, was about four in each group (Table 14). 
 
Table 14: Power analysis of the 7 spots changing according to Dago therapy, showing the minimum 













4.6  Validation of differences by Western Blot 
4.6.1  Disambiguation of multiple identifications 
In the LC-MS/MS identification of selected protein spots, a few double assignments occurred. In most 
cases, we refined them by matching with reference 2-DE maps (see Methods). In the case the 
ambiguous assignment was not resolved by matching, we checked the correct assignment by 
western blotting. 
Spot 382, for instance, was not confirmed as α-tubulin by Western Blot (Fig. 21) and therefore we 
assigned it to filamin-A, the second LCMS/MS identification with significant mascot score. Actually, 
alpha-tubulin is a highly abundant protein that localizes in the close proximity of spot 382, thus a 
contamination is expected to take place. 
 
Fig. 21: Verification of spot 382 as alpha-tubulin. Upper left: a detail of the 
original 2-DE map as shown in Figure 1. Lower left: antialpha-tubulin Western 
blot, with the region of interest in the red box. Upper right: registered 
Western blot after background subtraction and rescaling of the area 
boundaries using molecular weight markers and the anti-beta-fibrinogen 
Western blot as landmarks, with the corresponding region of interest in the 
red box. Lower right: overlay of the 2-bit Western blot (in red) with the 
original 2-DE map region. 
 
 
In a similar case, we ambiguously assigned spot 598 to serpin B9 and moesin. Western blot validation 
displayed that serpin B9 has a different localization on the 2-DE map (Fig. 22) and a repeated LC-






Fig. 22: Verification of spot 598 as serpin B9. Upper left: a detail of the 
original 2-DE map as shown in Figure 1. Lower left: anti betaactin (left) and 
anti-serpin B9 (small spot on the right) Western blot, with the region of 
interest in the orange box. Upper right: registered Western blot after 
background subtraction and rescaling of the area boundaries using molecular 
weight markers, the anti-beta-fibrinogen Western blot and the anti-beta-
actin Western blot as landmarks, with the corresponding region of interest in 
the orange box. Lower right: overlay of the 2-bit Western blot (in orange) 
with the original 2-DE map region. 
 
 
4.6.2  Total beta-fibrinogen levels are reduced in PD patients 
We clustered spot groups by aggregative nesting according to Pearson correlation (Fig. 23). Spots 
362, 365, 368 and 369, all corresponding to β-fibrinogen, were clustered in a single outgroup, 
showing the most stringent similarity among spots considered in each model. To verify their proper 
identification and confirm the differences observed by 2-DE with another technique, we measured 
total β-fibrinogen levels by Western blotting in three control subjects and three PD patients, taken 
from the training set, and correlated them to the sum of relative volumes for spots 362, 365, 368 and 
369 (r = 0.927; p = 0.003). Downregulation of β-fibrinogen involves all 2-DE isoforms, without an 



















 Fig. 23: Aggregated nesting based on linear Pearson 
 correlation (Eq. 1) of relative volumes of spot pairs. Bars 
















Fig. 24: Western blotting validation of beta fibrinogen. Panel A: Western 
blotting of total β-fibrinogen from six subjects selected among those enrolled 
in the biomarker discovery study. Panel B: Linear correlation of total β-
fibrinogen levels as measured by 2-DE spot volume and by Western blotting. 
The correlation coefficient is calculated according to Eq. 1. Panel C: Two 




4.6.3  Total transaldolase levels are increased in PD patients 
Spots 676 and 679, both corresponding to transaldolase, showed increased levels in PD patients by 2-
DE quantification and close correlation by aggregative nesting (Fig. 20). To confirm this finding we 
evaluated transaldolase expression by two-dimensional Western blotting. Fig. 25 shows the 
characteristic 2-DE pattern of transaldolase, with two trains of spots at different apparent molecular 
weight. In particular, its pattern was altered in three PD patients (two LO PD and one EO PD) with 
respect to three control subjects (two healthy subjects and one with atypical parkinsonism), patients 




Fig. 25: Two-dimensional Western blotting of transaldolase, showing two 
distinct pI distributions at different MW. Samples have been selected in the 
training set among those showing larger discrepancies in the 2-DE 
quantification to validate the correct assignment of protein spots. 
 
4.6.4  Validation of proteins changing with dopaminergic therapy 
The level change of both prolidase and peroxiredoxin 6 was validated by Western blotting, thus 
confirming results obtained by 2-DE experiments and mass spectrometry identifications. Fig. 26 
reports representative two-dimensional Western blots of prolidase (Fig. 26A) and peroxiredoxin 6 
(Fig. 26B) in PD patients assuming (Dago+) or not (Dago-) dopamine agonists. Relative protein levels 




staining in 2-DE gels (Fig. 27). Remarkably, the identity of ATP synthase subunit beta, F-actin capping 
protein subunit beta, tropomyosin alpha-3 chain and proteasome activator complex subunit 1 was 
assumed to be unambiguous on the basis of accurate matching with the reference 2-DE annotated 
map of human lymphocytes in the swiss-2dpage database (http://world-2dpage.expasy.org/swiss-
2dpage; entry LYMPHOCYTE_HUMAN; see Methods).  
 
 
Fig. 26: Western blot validation of prolidase and peroxiredoxin 6 altered 
levels. Panel A: representative Western blot of prolidase in patients under 
dopamine agonists treatment (Dago+) with respect to patients that do not 
assume dopamine agonists (Dago-). Panel B: representative Western blot of 
peroxiredoxin 6 in patients under dopamine agonists treatment (Dago+) with 





Fig. 27: Quantitative validation of prolidase and peroxiredoxin-6 expression. 
Protein levels (arbitrary units) measured by Western blotting are quantified 
with respect to β-actin and correlated to protein levels (arbitrary units) 





4.7  Further investigations on beta fibrinogen 
4.7.1  T lymphocytes and PBMC do not express beta fibrinogen. 
Since four spots with high weight were all identified as beta fibrinogen (Table 10) and since, after 
aggregative nesting, they showed stringent similarity (Fig. 23), we decided to deepen into this 
change, even because little is known about the link between beta fibrinogen, or fibrinogen in 
general, and T lymphocytes (or lymphocytes in general) (Ugarova and Yakubenko, 2001; Jennewein 
et al., 2011). 
Through RT-PCR we investigated the possibility that T lymphocytes or total PBMC from human 
subjects constitutively express beta fibrinogen (FGB). The experiment was simultaneously conducted 
also on Hep G2 cells, as a positive control. The expression for FGB at the transcriptional level was not 
detected for both T lymphocytes and PBMC (Fig. 28), despite of positive detection of FGB in HepG2 
cells. The expression of GAPDH in all cell types guaranteed the accuracy of the procedure used. 
 
 
Fig. 28: Expression at the transcriptional level of FGB and GAPDH 
(housekeeping) in PBMC, T lymphocytes and Hep G2 (positive control).  
Bands are visualized on a 2% agarose gel stained with ethidium bromide after 
RNA extraction, reverse transcription and PCR amplification.  
Lanes 1 and 5: blank for FGB and GAPDH primers, respectively. 
Lanes 2 and 6: PMBC from human subjects for FGB and GAPDH primers, 
respectively. 
Lanes 3 and 7: T Lymphocytes for FGB and GAPDH primers, respectively. 
Lanes 4 and 8: Hep G2 cells for FGB and GAPDH primers, respectively. 
 
 
4.7.2  Fibrinogen is not present on the cell surface of T lymphocytes. 
After being isolated from freshly obtained T lymphocytes, cell surface proteins and non surface 





Presence of fibrinogen was detected only in the fraction containing all proteins but surface proteins, 
while it was not detected in cell surface proteins. Beta tubulin was not detected in the cell surface 
protein fraction, as expected (Fig. 29).  
 
 
Fig. 29: Western blotting of beta fibrinogen (A) and beta tubulin (B) from cell 
surface protein fraction and non surface proteins. Samples of T lymphocytes 
from a PD patient and a control subject were loaded, together with a whole 
lysate of Jurkat cells as positive (for beta tubulin) and negative (for beta 





Table 15: LC-MS-MS identification of proteins. 


















      m/z charge start-end sequence 
Ion 
score 



































123668 5.51 110000 5.32 
 





















































ELLPVLISAMK  Ox(M) 
MSAEINEIIR Ox(M) 
MLGQMTDQVADLR  2Ox(M) 





























123668 5.51 110000 5.34 










































































      m/z charge start-end sequence 
Ion 
score 














































































QVQSLTCEVDALKGTNESLER Carbamidomethyl (C) 
LQDEIQNMKEEMAR  2 Ox (M) 



























































































































      m/z charge start-end sequence 
Ion 
score 


















































LAVNMVPFPR Ox (M) 




















362 Fibrinogen beta 
chain 













































55928 8.54 56000 6.20 
363 Protein disulfide-
isomerase A3 











































365 Fibrinogen beta 
chain 












55928 8.54 56000 6.37 
368 Fibrinogen beta P02675 ↓PD NA
a






















      m/z charge start-end sequence 
Ion 
score 
    
chain 
369 Fibrinogen beta 
chain 




164 – 178 





55928 8.54 56000 6.70 




2230 - 2245 





280608 5.70 58000 5.00 
392 Vimentin P08670 ↓LOPD 
 







































































































54348 5.47 55000 5.70 
405 Lymphocyte-specific 
protein 1 













































































      m/z charge start-end sequence 
Ion 
score 
    
441 ATP synthase 
subunit beta, 
mitochondrial 










95 - 109 
125 – 133 
134 - 143 
202 - 212 











56525 5.26 50000 5.17 
505 L-plastin variant Q59GX5 ↓LOPD 
 




























591 Vimentin P08670 ↑PD 59 2 656.38 2+ 391 – 401 MALDIEIATYR Ox(M) 59 53520 5.05 42000 5.45 























































67689 6.09 42000 5.60 
608 Actin-related protein 
2 










54 - 65 
54 - 65 
66 – 80 
181 - 187 
181 - 187 
DLMVGDEASELR Ox(M) 
DLMVGDEASELR Ox(M) 








8 6.30 40000 6.30 






















5.72 38000 5.80 
676 Transaldolase P37837 ↑PD 54 3 607.43 2+ 259 - 269 LLGELLQDNAK 54 37540 6.36 37000 5.78 







































      m/z charge start-end sequence 
Ion 
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protein subunit beta 
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2 - 12 
2 - 12      2 - 
12      13 – 27 
14 – 27 
14 - 27 
43 - 54 
43 - 55 
56 - 69 
70 - 76 
70 – 82 
77 - 89 
105 – 113 
105 - 113 
132 - 142 
143 - 153 
143 - 153 
154 - 162 
163 - 169 
163 - 169 
163 - 169 
163 - 169 
191-197 
198 - 208 
203 – 208 
203 – 208 
203 – 208 
216 –225 



























































29015 4.75 30000 4.75 






















      m/z charge start-end sequence 
Ion 
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36 - 45 
46 - 58 
59 - 70 
59 - 70 
59 - 72 
59 - 72 
142 - 155 
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156 - 166 





















28705 5.78 30000 5.64 






164 - 171 
210 - 228 




































22857 5.08 25000 5.00 












2 - 22 
98 - 106 
133 - 141 
133 - 142 






































146 – 162 
146 - 162 
201 - 215 
228 - 234 
235 - 248 
235 - 248 
324 - 334 
324 - 334 
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36031 8.26 25000 7.4 






















      m/z charge start-end sequence 
Ion 
score 
    






56 - 71 
76 - 82 







963 Proteasome subunit 
beta type-2 






20 - 29 
71 - 85 
171 - 181 






22822 6.51 23000 6.6 
1639 Beta actin
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19 - 28 
184 - 191 
197 - 206 
239 - 254 
315 - 326 













41736 5.28 26000 5.40 
1641 14-3-3 protein 
epsilon 












































































216 - 229 
457 - 469 
542 - 553 
708 - 715 
LANQAADYFGDAFK 
LLDEEEATDNDLR 



























Development and validation of disease-specific biomarkers for the diagnosis of early PD represents 
one of the most urgent needs in neurology (Shulman et al. 2011). The goal would be to find a reliable 
biomarker, or a panel of biomarkers, of PD in a peripheral and readily accessible compartment, in 
order to identify asymptomatic individuals with early-stage disease who may benefit from a 
neuroprotective or disease-modifying therapeutic intervention. 
In addition to sensitive and specific diagnostic biomarkers, there is also an urgent need for reliable 
surrogate biomarkers that can be used to accurately track progression of the disease. The developing 
of sensitive, specific, accurate, and reliable biomarkers in clinical trials of new disease-modifying 
therapies would permit to quantify their effectiveness with contained costs (Graeber 2009). 
In  this study, we showed that T lymphocytes proteome changes may be a valid measure both to 
predict the disease state in human subjects and to track progression and duration, but also to classify 
PD patients in terms of disease subtypes (e.g., EO vs LO patients). Our research is based on the 
rationale that T-cells show common features with dopaminergic neurons, with the clear advantage 
that peripheral cells are easily accessible, thus rendering them an ideal and amenable source for 
peripheral PD biomarker discovery. 
We supported the strength of such a rationale with our results: T lymphocytes change their 
proteome as a consequence of PD, a disease affecting dopaminergic neurons, and, notably, also long 
term dopaminergic therapy induces proteome changes that are expected in cells responsive to 
dopamine. 
The rationale for searching PD biomarker in peripheral blood lymphocytes (PBL) was previously 
proven by a "proof of principle" investigation conducted on advanced PD patients, where a 
proteomic profiling based on 2-DE of PBL was able to highlight differences at the peripheral level 
between patients and control subjects (Mila et al., 2009).  
The intrinsic feature of proteomics as a global and unbiased approach allowed us to explore a great 
universe of candidates without limiting to those that have been related to pathogenesis. In fact, we 
compared T lymphocyte proteomes in patients and control subjects by looking at whatever protein 
was showing a significant difference between the groups without knowing proteins' identities; as a 
consequence, we did not restrict our attention to proteins necessarily linked to any pathological 
process. However, their change at the peripheral level might reflect a central pathologic state due to 
modifications in cells (i.e., DA-ergic neurons) with some similar features with respect to the cells we 
have chosen as a source of biomarkers (i.e., T lymphocytes). Worth of note, the powerful ability of 2-
DE to identify quantitative changes in single protein isoforms or post-translational modifications 





Considerations about the predictive model. 
After having defined 20 spots showing quantitative differences between PD patients and control 
subjects (WIlcoxon test, p<0,05), their relative volumes were combined by LDA to obtain a predictive 
function able to classify an unknown subject as PD patient or control subject. The ability of this 
model in predicting PD was evaluated in terms of sensitivity and specificity, reaching a ROC AUC 
values of 0.906.  
This model was ameliorated when spots with lower weight were eliminated. In this way, we obtained 
a 14 spots- and a 9 spots-model both able to rightly predict thirty of 32 subjects as PD or control 
subject and ROC AUC values higher than 0.990. Although a validation on a larger cohort of subjects is 
needed, these values are suggestive of an excellent performance of both models. 
The high sensitivity of these predictive functions are certainly due to the significant inter-group 
differences of some proteins, but the main strength of our model is attributable to on the inclusion 
of a panel composed by several proteins rather than observing a single biomarker. Indeed, single 
biomarkers are difficult to identify, often display low specificity, and, especially when proteins are 
concerned, can be effectively influenced by drugs or habitual factors.  
A panel of biomarkers, instead, take into account several targets, that all together increase the 
specificity of the model, and it is unlikely that a confounding factor can interfere with more than one 
among the targets involved. Moreover, it is more robust with respect to the great intra-group 
variability expected in population-wide studies. As an example, high contribution to our model is 
given by four spots all corresponding to beta fibrinogen (see Table 7, spots 362, 365, 368 and 369): 
even if the weights of these spots are very high, their volumes alone are not able to rightly predict PD 
with acceptable sensitivity and specificity parameters. Moreover, a high level of fibrinogen in plasma 
is a marker of acute inflammation, so it would be difficult to assess low levels of the same protein as 
biomarker of PD, even if measured in T cells and not in plasma. 
Performance parameters obtained in this investigation need to be compared to similar biomarker 
discovery and validation studies appeared in the literature so far. As discussed in the introduction of 
this thesis, several papers on biomarker discovery are present in the literature, although most of 
them have not been validated on large scale. In some cases, authors attempted to diagnose PD on 
the basis of the measurement at the peripheral level of a single protein or gene transcript, but these 
proposed tests lacked sufficient sensitivity and specificity, or were not confirmed by others (see 
Morgan et al., 2010; Nyhlén et al., 2010; Alberio and Fasano, 2011; Gerlach et al., 2012). A marked 
improvement is achieved when two or more biomarkers are measured in order to predict a disease 
probability based on multiple observations. The panel of four gene transcripts measured in total 




showed good performance parameters in the discovery phase (Grünblatt et al., 2010; see 
Introduction), but, in our opinion, will possibly fail in the validation phase: actually, it is reasonable to 
expect low reproducibility and, in turn, low sensitivity due to the fact that the gene transcripts were 
selected on the basis of their altered levels in the SNpc. On this ground, it is unlikely that these genes 
maintain the observed differential expression in a distinct compartment. 
A different comment could be made on biomarkers proposed by Mollenhauer and coworkers 
(Mollenhauer et al., 2011): they measured concentrations of α-synuclein, tau and total protein in CSF 
of patients with PD, Alzheimer Disease, Dementia with Lewy bodies, MSA, and non-
neurodegenerative neurological disorders (overall patients n = 273), defining a very accurate 
predictive model (ROC AUC = 0.909 for the training set), but in a subsequent validation phase (n = 
304) the classification of PD patients displayed a reduced ROC AUC of 0.706. Although in this case the 
rationale for the choice was strong and the number of patients was impressive, we think that the 
cross-validation performance turned out to be unsatisfactory because the number of targets was 
small. Moreover, it has to be considered that a study contemplating CSF specimens is more difficult 
to carry on, due to the discomfort associated with CSF sampling. 
One of the most promising studies, still to be validated, is the one proposed by Bogdanov and 
coworkers, that used an unbiased approach: they proposed a metabolomic profiling that correctly 
classified PD patients (n = 66) and control subjects (n = 25) in a cross-validation procedure by 
permutation test (Bogdanov et al., 2008). 
Due to the global approach we used, and the number of targets forming our models, we expect that 
performance parameters will not worsen significantly in a further clinical validation phase, in 
particular for the models of 14 and 9 spots because they have higher ROC AUC values. In addition, 
the model composed by 9 spots is the most suitable for an antibody-based validation test (e.g., 
ELISA) because of the relatively low number of targets to be measured.   
We intentionally avoided to focus on the identity of selected proteins. Indeed, every single protein is 
far from being a significant element for PD early diagnosis (Alberio and Fasano, 2011; Surinova et al., 
2011). However, some considerations about identity of changing protein can be made: some details 







Table 16: List of proteins included in the predictive models, with their relative functions, subcellular 
localization and tissue specificity. Proteins corresponding to more than one spot are not 











Actin filament (F-actin)-binding protein 
involved in cell-matrix adhesion and cell-
cell adhesion. May also play important 
roles in cell morphology and locomotion. It 
is the cytoplasmic face of adhesion 
plaques. Recruitment to cell-cell junctions 











Vimentins are class-III intermediate 
filaments found in various non-epithelial 
cells, especially mesenchymal cells. 
Vimentin is attached to the nucleus, 
endoplasmic reticulum, and mitochondria, 










Probably involved in connections of major 
cytoskeletal structures to the plasma 
membrane. High molecular weight 
cytoskeletal protein concentrated at 
regions of cell-substratum contact and, in 















Fibrinogen has a double function: yielding 
monomers that polymerize into fibrin and 
acting as a cofactor in platelet aggregation. 
Secreted. Plasma, liver 
Filamin-A P21333 
Promotes orthogonal branching of actin 
filaments and links actin filaments to 
membrane glycoproteins. Anchors various 
transmembrane proteins to the actin 
cytoskeleton and serves as a scaffold for a 
wide range of cytoplasmic signaling 










May play a role in mediating neutrophil 












Filament-forming cytoskeletal GTPase. 
Required for normal organization of the 



















Probably involved in connections of major 













protein that binds to the plus (or barbed) 
ends of actin monomers or filaments, 
preventing monomer exchange (end-
blocking or capping). It can promote the 
assembly of monomers into filaments 
(nucleation) as well as sever filaments 
already formed. Plays a role in ciliogenesis. 
















Transaldolase is important for the balance 






Actin-binding protein involved in motile 
and morphological processes. Inhibits actin 
polymerization, likely by sequestering G-
actin. By capping the barbed ends of 
filaments, it also regulates motility. Seems 
to play an important role in clathrin-















Regulates the GDP/GTP exchange reaction 
of the Rho proteins by inhibiting the 
dissociation of GDP from them, and the 





Actins are highly conserved proteins that 
are involved in various types of cell motility 









Adapter protein implicated in the 
regulation of a large spectrum of both 
general and specialized signaling pathways. 
Binds to a large number of partners, usually 
by recognition of a phosphoserine or 
phosphothreonine motif. Binding generally 
results in the modulation of the activity of 







Most of changing proteins are part of the cytoskeleton or are involved in cytoskeletal functions; this 
is a common finding in proteomic studies (Petrak et al., 2008), due to the considerable size of this 




predictable, as it is reasonable that if T cells sense any alteration (for example due to PD), they 
respond in adaptation of their prominent functions, that are, among others, ability of extravasation 
and increase of motility. Some proteins, not related to cytoskeleton, reflect key activities of T cells; 
for instance, the lymphocyte-specific Protein 1, that participates in signaling with other immune cell 
types. Other proteins take part to biochemical pathways common to many tissues (transaldolase, 14-
3-3 epsilon, Rho GDP dissociation inhibitor isoform 2). On the other hand the presence of beta 
fibrinogen, expressed only by hepatocytes and present in plasma at high concentration is definitely 
unexpected (see below). 
It would be interesting to investigate the reasons why T cells change levels of these selected proteins 
as a mirror of the central disease, even if it goes beyond the purpose of our study. However, T cells 
might not reflect the same alterations present in affected neurons. What we wanted to point out 
was a protein fingerprinting of the disease state, more than a functional correlation between 
proteins altered at the central level and those that mirror neurodegeneration at the peripheral level. 
 
 
Considerations about progression trackers  
 
We demonstrated that a total of 9 spots of the 2-DE gel display linear correlation with parameters 
such as disease duration (expressed as years from onset) and disease progression (expressed as 
Hoehn and Yahr score). In particular, four spots correlate with duration, and 8 spots correlate with 
progression of symptoms; 3 of them correlate with both duration and progression.  
Progression of symptoms do not correlate linearly with duration of the disease. In fact, PD is a 
multifactorial disease and various forms of PD have been reported, being patients classified in 
different subtypes depending also on the rate of worsening of symptoms or predominance of some 
symptoms on the others (Shulman et al., 2011). For example, between genetic forms we can 
distinguish forms characterized by rapid progressive course and frequent development of dementia 
(SNCA mutations forms) or slightly more clinically benign, tremor-predominant forms (LRRK2 
mutation forms).  
Moreover, duration of disease is a parameter difficult to measure: the onset of the disease precedes 
the appearance of symptoms by many years and, when motor symptoms appear, these are 
recognized by patients in a subjective way. This is especially true for motor signs other than tremor, 
that might not be associated to PD for a long time. In our opinion, this is the reason why we found 
only four spots correlating with this parameter; more spots could correlate with duration if it was a 




Then, we propose two distinct linear functions able to track separately duration and progression. 
Both of them show discrete correlation coefficients (r = 0.516 and 0.674, respectively) with statistical 
significance (p = 0.049 and 0.006), and were improved by adding control subjects at x = 0. 
To the best of our knowledge, few reports pointed out to molecular biomarkers predictive of PD 
progression (Mila et al., 2009), whereas some attempts have been made to find correlation between 
functional imaging biomarkers and disease staging (Marek et al., 2011; Gerlach et al., 2012). Evidence 
of underlying PD progression before the appearance of motor signs together with an advisable 
neuroprotective treatment would stop disease progression at the prodromic stage. Given the 
common features between T-cells and dopaminergic neurons, T-lymphocyte proteome biomarkers 
may reasonably report on the effectiveness of future (or under development) drugs which would 
interfere with specific cell death mechanisms that target nigral neurons. 
 
 
Considerations about classification of PD subtypes  
As discussed above, PD is a multifactorial disease, with substantial heterogeneity in its presentation, 
so that some neurologists argue in favor of abandoning PD as a single clinico-pathologic entity, 
instead enumerating many subtypes on the basis of varying clinical features, familiality, and autopsy 
findings (Shulman et al., 2011). Taking again as an example genetic forms, the majority of idiopathic 
and genetic PD patients display, on autopsy, LB in surviving DA neurons, so that their presence is an 
hallmark of PD. Nevertheless, absence of Lewy bodies in patients with parkin mutations has been 
noticed, with clinical signs mostly similar to idiopathic PD (Shulman et al., 2011; Chung et al., 2001). 
Considering clinical manifestation, subtypes of patients may be recognized on the basis of the age at 
the onset, predominant clinical features and the progression rate. Tremor predominant forms are 
often observed in younger people, while bradikynesia-predominant forms and a type known as 
“postural imbalance and gait disorder” (PIGD), characterized by akinesia, rigidity, and gait and 
balance impairment, are often observed in older people (Obeso et al., 2010). 
In our study we include “typical” patients, with absence of atypical signs and a good response to L-
DOPA. Because of the restricted number of patients included in this study, it would be unproductive 
subdividing  them into various subtypes, so we prefer to verify if spot volume differences correlate 
with a single, major factor of patients' heterogeneity, the age at onset. In fact, aging is the most 
important risk factor for developing PD, being only 3% of cases initially recognized in individuals 
younger than age 50. Moreover, patients with young onset have more frequently a positive family 
history, this suggesting that genetic forms cause a parkinsonism that manifests earlier, by impairing 




We subdivided the PD group into two subgroups, EOPD patients and LOPD patients; the number of 
components of the two groups was comparable because we specifically enriched the patients group 
in EOPD patients to highlight possible effects due to the genetic background, as they have increased 
probability to carry a familiar form of PD respect to PD patients. 
We found 7 spots whose volumes statistically changed in the EO and LO PD groups. We performed a 
linear discriminant analysis on selected spots so to obtain a likelihood score (a linear combination of 
relative spot volumes) able to correctly classify EO PD patients (ROC AUC = 0.911; Fig. 17), with the 
same "leave-one-out" procedure described and discussed above for the three predictive models. The 
fact that we were able to distinguish two subtypes of PD patients by analyzing the T cells proteome in 
a relatively small number of patients allows us to confirm that T-lymphocyte proteome changes are a 
valid tool to correctly classify PD patients. 
In the validation phase of this project, the enrolment of a larger number of patients will allow us to 
evaluate the possibility to classify PD patients in terms of clinical subtypes, aiming at a personalized 
therapy. 
Moreover, as the younger onset is often a signal of a possible genetic cause of the disease, our 
discrimination of EO/LO patients could also be seen as an potential tool to discriminate familial and 
sporadic forms of the disease. The effectiveness of this achievement might be of great relevance for 
the identification of patients carrying new genetic forms, characterized by low penetrance, where 
linkage disequilibrium studies are not appropriate. Remarkably, this is the first report of peripheral 




From 2-DE images of gels acquired and detected with the appropriate software we obtained the 
relative volume of each spot in every single map. As expected, the distribution of spot volumes 
deviated from normality and intra-group variance values were dissimilar, therefore a parametric test 
was not a suitable choice (Fig. 30). We chose the non-parametric Wilcoxon test, as it compares 
median instead of mean values, to detect  differences correlated to various parameters (disease, 







Fig. 30: In any symmetric (normal) distribution, mean, median and mode 
coincide, while in asymmetrical distribution they do not. The mean is 
influenced by the limit values, while the median best reflect the values 




On the other hand, LDA assumes that variances of distinct groups are similar. For this reason, 
inclusion of all 20 spots in the classification model did not grant the best result. In an original way, we 
manually calculated the weight of each spot in the model (Eq. 3), so to exclude those with a limited 
contribution. In this way, performance parameters of the models were markedly improved (Table 9). 
Moreover, a model composed by 20 spots is difficult to use in subsequent validation analysis: in fact, 
a simplified analytical test will be proposed for the measurement of levels of selected proteins on 
large scale. It would be preferable to use an antibody-based assay like ELISA rather than 2-D 
electrophoresis, that is the ideal technique for the discovery phase but it is not suited for a screening 
phase, due to the time required for each analysis and the need of highly-specialized personnel.  
The model composed by 14 spots is very promising, nevertheless we further excluded spots with 
lower contribution in order to find a third model with a reduced number of spots with still 
comparable performance parameters. The model composed by 9 spots possess both the attributes: it 
has good specificity and sensitivity and is composed by a low number of targets, so to be suitable for 
the development of an easy and ready-to-use test applicable on population-wide scale. 
Several biomarker discovery investigations do not take into account the effect of medication on 
proteome or gene expression profiles. This aspect is particularly relevant when dealing with T-cells, 
expressing dopamine receptors, in patients treated with dopamine agonist drugs. In fact, we found 
several spots whose volume was correlated to dopaminergic therapy (see below). Apart from 
enrolling a small number (n = 3/15) of de novo patients, we separately considered the effect of 
dopamine agonist treatment and of L-DOPA daily dose on the T-cell proteome, thus excluding from 




discovery procedure of the predictive models those spots that showed significant correlation with 
the age of control subjects only. Since age is the main risk factor of PD, proteome changes due to age 
were considered as biases and were eliminated from the dataset in which differences depending on 
disease or therapy were searched in. 
A limitation that may be envisaged in the present investigation is the limited number of cases and 
control subjects included in the study. Nevertheless, we have enrolled a sufficient number of subjects 
(about 15 per each group) based on established guidelines for biomarker discovery studies. Being 
aware that, in the ideal biomarker pipeline, discovery, verification and validation should be 
decoupled steps of a phased approach (Surinova et al., 2011), we have attempted to evaluate intra-
group variance and the difference of mean values for each spot included in the models and to 
perform a power analysis of our study. On this basis, we assured that the minimum number of 
subjects required to verify the observed variation is in the 10-20 range, thus permitting an 
appropriate verification on the same data set by the leave-one-out validation procedure. Worthy of 
note, we measured protein levels in the verification step in the same cellular population where the 
discovery procedure was conducted, thus avoiding issues frequently emerging when using plasma 
and CSF samples (i.e., high dilution of the candidates in the body fluid and mixture with components 
coming from different body compartments). In this context, enrolment of larger cohorts in the 
verification phase of the biomarker pipeline would not add much value to the significance of our 
results (Surinova et al., 2011). 
 
 
Validation of changes by Western Blot 
In order to validate the results obtained by the proteomic approach with an independent technique, 
we conducted Western Blot quantifications on the same samples used for the 2-DE maps in order to 
verify those changes that seemed more significant. 
We used this technique to univocally clarify double identifications. For two spots, in fact, matching 
with reference 2-DE maps was not sufficient to understand which protein was involved in the 
observed change, or because of problems of co-migration, or because of contamination of other 
proteins migrating in the near space of the 2D gel. In both cases, we run the samples in the same 
conditions used for obtaining the maps but, instead of staining the resulting gels with the fluorescent 
dye, proteins were transferred to 18x18 cm2 PVDF membranes that were subsequently incubated 
with the antibody against one of the suspected proteins (Fig. 21). Then we overlapped images from 
Western Blot with 2-DE maps, taking as landmarks beta actin and validated identifications, like 




identification by a process of elimination. One of them, the spot 598, was confirmed to be Moesin by 
a repeated LC-MS/MS analysis. 
Regarding spots that belong to the predictive models, we verified beta fibrinogen and transaldolase 
changes. The first protein was chosen because 4 spots were identified as beta fibrinogen and 
appeared to be correlated by aggregative nesting (Pearson linear correlation, see Fig 23). Moreover, 
the contribution of beta fibrinogen appeared to be prominent in all three models in terms of its 
weights as calculated by Eq. 3 (Table 10). Noticeably, they also correlated linearly with the 
progression of the disease, thus highlighting the importance of this protein in the present study. 
Because all four spots of beta fibrinogen were downregulated in PD patients, we validated them in a 
one-dimensional Western Blot. Remarkably, total beta fibrinogen levels displayed a perfect 
agreement with the proteomic quantification (Fig 24B). We also checked the 2-DE pattern of beta 
fibrinogen in a PD patient and in a control subject, to exclude a significant qualitative modification of 
relative volumes of some isoforms with respect to others (Fig 24C). We observed several spots 
recognized by the anti-fibrinogen antibody, probably more than four, but their volume changes are in 
the same direction.  
These findings show interesting complementarities with the preliminary evidence that two different 
isoforms of gamma fibrinogen either correlate with the disease state or with the disease duration in 
PBL (Mila et al., 2009). Although little is known on the role of fibrinogen in lymphocytes, it is notably 
that we found changing the same protein (also if a different fragment) in two independent, global 
approaching experiments conducted in similar cellular systems. Apparently, whatever the role of 
fibrinogen in lymphocytes, far from being elucidated, its abundance in T lymphocytes is unbalanced 
in PD patients and the reason of this observation needs to be further investigated (see below). 
Two spots both identified as transaldolase show increased levels in the 20-spot model. Transaldolase, 
a key enzyme in the pentose phosphate pathway (PPP), has been associated with regulation of 
apoptotic cell death both in cancer and in neurodegeneration (Samland and Sprenger, 2009). The 
protein has a characteristic pattern in 2-DE, with two trains of spots at slightly different apparent 
molecular weight (Lachaise et al., 2001). Pattern modifications have been linked to regulation of the 
PPP by protein kinase transduction pathways. When comparing two LO PD and one EO PD patients 
with two healthy subjects and one with atypical parkinsonism it becomes clear that PD patients have 
a remarkably higher abundance of the heavy isoform (Fig. 25). 
Two proteins changing with dopaminergic therapy were also validated through Western Blot: 
prolidase and peroxiredoxin 6 (Fig. 26). Also in this case, we obtained overlapping of the results from 
proteomics and antibody-based technique results (Fig. 27), thus confirming both the accuracy of 





Dopaminergic therapies modulate T cell proteome of PD patients 
We demonstrated that specific stimulation of dopamine receptors has important effects on T-cell 
proteome in patients under long term treatment with dopamine agonists (Alberio et al., 2012b), thus 
confirming the concept that T lymphocytes are dopamine-susceptible cells, and they are reasonably 
modified by dopaminergic stimulation. Indeed, D3 stimulation of T-lymphocytes raises levels of 
prolidase, actin-related protein 2, F-actin capping protein subunit beta, proteasome activator 
complex subunit 1 and peroxiredoxin 6, and lowers levels of tropomyosin alpha-3 chain and of an 
isoform of GAPDH. Despite the limited number of spots displaying significant changes, dopamine 
agonists effectively alter the proteome of T-lymphocytes. Changes in cytoskeletal or cytoskeleton-
related proteins (actin-related protein 2, F-actin capping protein subunit beta, and tropomyosin 
alpha-3 chain) are consistent with a remodeling of T-lymphocyte cellular architecture induced by 
dopamine receptor stimulation (see Alberio and Fasano, 2011).  
Prolidase (also known as peptidase D) is a member of the prolyl oligopeptidase family able to 
hydrolyze dipeptides or tripeptides with C-terminal proline or hydroxyproline residues (Lupi and al., 
2008). Actually, prolidase expression is higher in T-lymphocytes of PD patients undergoing dopamine 
agonists treatment. Worth of note, a member of the proline-specific peptidase family regulates 
apoptosis in quiescent lymphocytes (Chiravuri and Huber, 2000).  
Upregulation of peroxiredoxin 6, observed in 2-DE maps and confirmed by Western blotting, is a 
relevant hint of antioxidant defense challenged by dopamine agonist treatment at pharmacological 
level in PD patients (Manevich and Fisher, 2005). It was observed that peroxiredoxin 6 and 
proteosome activator complex subunit 1 are downregulated in human lymphocytes treated with 
H2O2 (Dahlan et al., 2012). The fact that we observe the opposite effect might be due to the specific 
action of dopamine agonists on dopaminergic receptors, therefore excluding an aspecific effect due 
to generic oxidative stress.  
Protein changes discussed above have not been correlated with the daily dose of dopamine agonists 
because patients assume different drugs (ropinirole, pramipexole and rotigotine) with different 
pharmacokinetic profiles; therefore, we stratified PD patients in terms of a general stimulation of 
dopamine receptors in order to avoid false correlations due to differences in subjects’ metabolism 
and combination of drugs in their therapy. It should be noticed, however, that all dopamine agonists 
display specific stimulation of D3 dopamine receptors (Beaulieu and Gainetdinov, 2011), thus 
suggesting that a similar receptor-mediated effect would be expected. 
Conversely, we found that L-DOPA induces limited modifications in the proteome of T lymphocytes. 
Indeed, only two display significant linear correlation with the L-DOPA daily dose, that were 




with the observation that lymphocytes of PD patients under L-DOPA treatment do not display 
increased oxidative chromosomal damage (Oli et al., 2010) and that exposure to L-DOPA does not 
modify dopamine transporter expression at central level as well as in PBLs of PD patients (Fanciulli et 
al., 2011). On the other hand, the identification of a significant decrease of proteasome β subunit 
type-2, a component of the proteasome aimed at the degradation of oxidatively-modified proteins, 
appears to counteract the observation of increased proteasome α subunit in striata of dyskinetic L-
DOPA treated rats (Valastro et al., 2007). Although several models of proteasome impairment have 
been developed to understand altered protein homeostasis in PD (see Alberio and Fasano, 2011; 
Alberio et al., 2012a), this study first disclose a functional relationship between different proteasome 
subunit levels and L-DOPA therapy. On the other hand, the observed increase in ATP synthase β 
subunit may reflect a general adaptation of energetic metabolism to an altered turnover of reactive 
oxygen species (Petrak et al., 2008). 
This section of our study may be limited by the relatively small sample size of drug naïve patients (3 
patients), as well as by the lack of a cross-sectional perspective. An ideal approach, which we are 
planning to pursue in future studies, would imply a direct comparison of T-cell proteome from each 
patient before and after a given period of treatment. Nevertheless, it is likely that most changes we 
observed would emerge only in the long term, thus rendering the longitudinal approach difficult to 
pursue. 
Beyond the interesting results we obtained regarding correlation between long term dopaminergic 
therapy and changes in the T cell proteome, two considerations have to be done: first, we initially 
searched for changing spots in order to exclude them in the analysis for biomarker discovery, as 
differences correlated to therapy could act as confounding factors, being borne by the patients’ 
group only. Secondly, our results are in keeping with recent studies focusing on the role of dopamine 
in regulating T-cell activity (Pacheco et al., 2009; Sarkar et al., 2010), suggesting that 
immunomodulatory therapies using dopamine agonists and antagonists might have a potent 
rationale, being T lymphocytes modified by dopaminergic therapy. 
 
 
Focus on Beta Fibrinogen 
One of the most impressive changes identified in our study is that regarding the total beta fibrinogen 
level. As stressed before, four spots that considerably contribute to the predictive model correspond 
to beta fibrinogen (Table 7; see Fig. 24 for Western blot validation), showed stringent clustering by 
aggregative nesting (Fig. 23) and correlated with progression and duration of disease. Moreover, two 




duration in PBLs (Mila et al., 2009). Both evidences of fibrinogen imbalance in lymphocytes of PD 
patients prompted us to further investigate this protein in our cellular system. 
 
Fibrinogen (also named coagulation factor I) plays an essential role in the hemostatic system by 
bridging activated platelets and being the key substrate for thrombin in establishing a consolidating 
fibrin network. Fibrinogen is synthesized in the liver and the plasma concentration is 1 to 5 g/L 
(Sørensen et al., 2012).  Fibrinogen is a complex multifunctional glycoprotein composed of two 
identical molecular halves, each consisting of three non-identical subunit polypeptides designated as 
alpha (Aα), beta (Bβ), and gamma (γ) chains, held together by multiple disulfide bridges. The amino 
terminal ends of Aα and Bβ chains represent fibrinopeptides A and B (FPA and FPB), and are cleaved 
when thrombin transforms fibrinogen into fibrin during the coagulation process (Fig. 31A). 
Fibrinogen has a trinodular structure; one central dimeric E domain in which each dimer contains the 
three amino-terminal regions of polypeptides, and two distal D domains. These three nodules are 
linked by two coiled-coil regions and contain multiple binding sites (Fig. 31B) (Sørensen et al., 2012; 




Fig 31: A) schematic representation of  polypeptide chains composing fibrinogen 
molecules and highlight of cleavage sites of thrombin: from the amino terminal 
ends of Aα and Bβ chains, Fibrinopeptide A and Fibrinopeptide B (represented by a 
rectangle and a cylinder, respectively) are cleaved, while chains α, β and γ 
rearrange to form the fibrin coat. B) representation of trinodular structure of 
fibrinogen: domain E, containing amino-terminal connecting regions of the three 
chains, is located among the two distal D domains, composed by the three 
polypeptide chains α, β, and γ (adapted from Ugarova and Yakubenko, 2001). 
 
 
Beyond its prominent role in the coagulation process, numerous studies provided evidence that 
fibrinogen also plays a multifaceted role in the immune and inflammatory response (Colvin et al., 




of fibrinogen to participate in the inflammatory response depends on its specific interaction with 
leukocyte cell surface adhesion receptors (e.g., integrins). In particular, two leukocyte integrins, αMβ2 
(also known as Mac-1 or CD11b/CD18) and αXβ2 (CD11c/CD18, p150,95) are the main fibrinogen 
receptors expressed on neutrophils, monocytes, macrophages and several subsets of lymphocytes, 
as well as on the surface of endothelium cells (Ugarova and Yakubenko, 2001). 
The ability of fibrinogen to bind to these receptors indicates the existence of a potential fibrinogen-
dependent pathway for leukocyte-endothelium interaction in vivo. In this regard, recent studies 
demonstrated that simultaneous fibrinogen binding to leukocytes and endothelial cells did enhance 
adhesion of monocytes to endothelium by acting as a molecular bridge between the two cell types 
(Languino et al., 1995). Most studies regarding the fibrinogen-leukocytes interaction focused on Mac-
1 binding sites for fibrinogen, a very complex question as integrins usually recognize more than one 
molecule (Mosesson 2005; Lishko et al., 2004), while only few concentrate on action of such 
stimulation (Flick et al., 2004). It is known, however, that integrins’ adhesive function is directly 
coupled with intracellular signaling and reorganization of actin cytoskeleton, that is in line with the 
concept that fibrinogen provokes leukocyte attraction and enhances activation and extravasation 
(Ugarova and Yakubenko, 2001). 
Elevated levels of plasma fibrinogen are usually reduced in patients with clotting system’s problems, 
while high levels are associated with inflammation and with thrombotic complications (Tousoulis et 
al., 2011). Altered fibrinogen levels have never been detected in plasma of PD patients, neither were 
associated with other neurodegenerative disorders. On the other hand, clinical chemistry analysis in 
50 PD patients and 50 control subjects affected by non-neurodegenerative neurological disorders 
(e.g., stroke) displayed elevated fibrinogen levels in the control group (Alberio et al., submitted). It 
should be noticed, however, that fibrinogen levels might be raised in subjects with hemorrhagic 
events or brain infarction.  
Regardless of a change in plasma beta fibrinogen levels, this protein appears to be surprisingly 
abundant in T lymphocytes (Fig. 32). Considering that beta fibrinogen is expected to be abundant in 
plasma and in liver only (Table 16), its presence in T cells was found to be qualitatively elevated when 
the four selected spots of beta fibrinogen are compared with the most abundant protein (i.e., 





Fig. 32: A 2-DE map of T lymphocytes from a control subject, where beta 




The first question we posed is if T lymphocytes, or more generally PBMC from human blood, do 
synthesize beta fibrinogen by their own or take it from the medium. We conducted a RT-PCR 
quantification of the beta fibrinogen transcript in T cells, PBMC and Hep G2 cells, as a positive 
control. We found that neither T cells neither PBMC constitutively express beta fibrinogen at a 
detectable level (Fig. 28). If beta fibrinogen is not expressed by T cells or PBMC themselves, we 
should hypothesize that it is necessarily internalized from the blood. However, little is known about 
internalization processes of fibrinogen by lymphocytes. An interesting research conducted on 
neutrophils proposes that, in the presence of physiological concentrations of fibrinogen, 
internalization of both intact and degraded forms of fibrinogen occurred largely via a non-specific 
pinocytosis process (Kirsch et al., 2002). In order to understand the nature of the fibrinogen 
internalization process by T lymphocytes, we tried first to localize the beta fibrinogen either at the 
cell surface or in the cytoplasm. To this purpose, we specifically labeled proteins at the T cell surface 
so to separate these proteins from the whole protein content. As a result, fibrinogen was not 
detected by Western blot in the fraction containing cell surface proteins (Fig. 29). Conversely, it is 
present in the whole protein content deprived of surface proteins. This result is in line with the 




As fibrinogen circulates in blood in its hexameric conformation (Sørensen et al., 2012), it is 
reasonable to assume that it is internalized in its intact form. The fact that we observed a significant 
change only for beta fibrinogen may reflect a crowding in the 2-DE map that hampers the 
appropriate quantification of the other chains. Alternatively, this finding might depend by other 
unexpected phenomena, such as differential degradation. In support of the first hypothesis, the PD 
related quantitative change of gamma fibrinogen in PBL previously observed (Mila et al., 2009) seems 
to delineate an alteration in internalized fibrinogen that involves all polypeptide chains. 
In conclusion, this investigation on the role of beta fibrinogen in peripheral T cells, and especially on 
the reason why its amount is reduced in T cells of PD patients, needs further work. On the basis of 
present results, we speculate that it is internalized in relatively large amounts, but the internalization 
could be impaired by various causes. If such internalization occurs via endocytosis (this would explain 
the large amount we observed in our cells) or pinocytosis (as it apparently happens in neutrophils, 
see Kirsch et al., 2002), the differences we observed in cytoskeleton proteins (Table 16) could 
participate to the same context: indeed, modifications of the cytoskeleton system could also reflect 
in decrease of content of intracellular amount of proteins internalized from plasma, such as 
fibrinogen. Nevertheless, we prefer to speculate on a mechanism that contemplate specific 
recognition of fibrinogen, because of the powerful significance of the PD-related quantitative change 


















In this thesis the discovery phase of a broader study of biomarker identification for PD is presented. 
As stated by Surinova and coworkers, a discovery study should deal with a small sample of 
homogeneous subjects to be screened by an unbiased technique to generate a quite large number of 
candidates; these candidates need to be verified, for instance using a jackknifing (leave-one-out) 
procedure. After candidates have been individuated, they need to be (pre-)clinically validated using a 
different, high-throughput methodology across large cohorts of patients and control subjects 
(Surinova et al., 2011). 
In this study, a relatively small number of PD patients and control subjects has been analyzed and 
differences in a peripheral compartment, that is biochemically related to the central nervous system 
area involved in PD, have been found. The ideal flowchart of a proteomic investigation for a 
biomarker discovery strategy, described in Fig. 3 (see Introduction) has been followed, and three lists 
of potential biomarker candidates have been proposed. 
Now a challenging phase of the project faces these results: leading the current finding to the clinical 
practice, with the final aim of proposing a biomarker panel for the in vitro diagnosis of Parkinson's 
disease. To do that, a validation procedure has to be planned and put into practice, creating a 
network between neurology divisions (whose task is enrolling and stratifying PD patients and control 
subjects), analysis laboratories (that would provide the correct procedure for sampling and 
measuring selected targets) and, obviously, the unit that will arrange and statistically analyze data 
obtained by collaborators. 
A schematic representation of differential purposes of these two distinct phases of a biomarker study 
is provided in Fig. 33. 
The validation phase needs to be conducted on a far more abundant number of subjects. In our case, 
some considerations about subjects enrollment have to be done: first, we have to enlarge control 
subjects’ group and render it less homogeneous: subjects with other diseases, e.g., inflammatory 
diseases, subjects taking drugs, subjects of different ethnicity and subjects with family history of PD 
have to be included, as we need to test our models also in conditions not so controlled as the ones 
we used for the discovery phase. Since our models are composed by several proteins, we expect that, 
also  if some of them are influenced by other (pathological) conditions, the contribution given by the 
other (not influenced) targets will permit to calculate the right predictive score. Secondly, by 
increasing the PD patients number, it will be possible to include and stratify different PD subtypes, as 
well as patients with varied state of progression and years of disease, so to confirm our preliminary 
results about capability of monitoring progression and differentiate PD subtypes of some protein 
candidates. In order to validate disease progression, patients could be followed up in a longitudinal 
study; moreover, samples taken for the validation could be used to deeply investigate modifications 








Fig. 33: Differences in methods and intents of the discovery and validation 
phases of a biomarker identification project. 
 
 
Also standardization of sampling is necessary if enlargement of the collaboration network is planned. 
Unfortunately, collection of T lymphocytes from whole blood is a time and cost consuming 
procedure, so a further more accessible cell system in which to perform validation should be 
advisable. To this purpose, some experiments are in progress in our laboratory to test the possibility 
that the differences we found in T cells could be detected also in PBMC or PBL, also to verify a 




If 2-DE is one of the techniques of choice for the discovery phase (see Introduction and Discussion),  
it would be advisable to use a different approach for the validation phase, due to the time required 
for each 2-DE analysis and the highly-specialized personnel it requires. In our cases, a technique able 
to discriminate different isoforms of the same protein is needed. In fact, some proteins showed a 
difference in volume of some isoforms that are not necessarily detected in others (e.g., transaldolase 
only changes in its higher molecular weight isoforms, Fig. 25), and a quantification of their total 
content would be unproductive for our purposes. For this reason, antibody-based approaches have 
to be excluded.  
Mass spectrometry-based approaches are more suitable for the validation phase. In particular, the 
Selected reaction monitoring (SRM) method is especially suited for the high-throughput screening of 
a number of different targets, simultaneously (Wang et al., 2011). Briefly, it consists in the ionization 
of the samples in an electrospray source, selection of peptide precursors that are then isolated and 
fragmented so to obtain product ions whose signal abundances are indicative of the abundance of 
the peptide in the sample (de Hoffmann 1996). In this way, once peptides characteristic of proteins 
(and isoforms of proteins) to be quantified are individuated, the analysis consists in measuring 
abundance of such peptides in each sample, with the possibility to quantify several peptides (and 
consequently several proteins) in the same analysis. Difficulties in beginning this achievement are 
represented by the high costs of the instrument.  
Concerned to the role of fibrinogen on T cells, it would be interesting to understand the reasons of 
the diminished amount that we observed in PD lymphocytes. Experiments addressed to establish if 
and how T lymphocytes (and/or other circulating cells) internalized it are, in my opinion, the most 
urgent. This could be reached both using cellular models and analyzing human samples. The cellular 
model of Jurkat cells, for example, that we showed to be fibrinogen free, could be treated with 
fibrinogen or plasma in order to detect the presence of FGB by Western Blot after a time course-
treatment. In the case of a positive result, the process of internalization would be confirmed. We are 
also planning a cytofluorimetric analysis of freshly isolated PBMC from PD patients and control 
subjects, treated with FITC-labeled fibrinogen, in order to quantify the amount of internalized 


















 T lymphocyte proteome changes have been shown to be a valid tool to recognize and classify 
PD patients. A biomarker discovery procedure has been conducted on the basis of common 
features between affected cells (dopaminergic neurons) and the probed system (T 
lymphocytes). 
 
 We found 20 T cell proteins whose level was significantly different in PD patients and control 
subjects; their volumes were combined by LDA to calculate a PD likelihood score and classify 
each subjects as PD patient or control.  
 
 Three predictive models were obtained, one combining all 20 changing spots, the second one 
combining only 14 spots, while the third  is composed by only 9 spots. Models with 14 and 9 
spots showed best parameters of sensitivity and specificity. Performance of the models was 
tested with the leave-one-out method. 
 
 A total of 9 spots display linear correlation with parameters such as disease duration (years 
from onset) and disease progression (Hoehn and Yahr score). In particular, four spots 
correlate with duration, and 8 spots correlate with progression of symptoms; 3 of them 
correlate with both duration and progression. A panel of biomarkers able to track 
progression of the central disease at a peripheral level is expected to reasonably provide 
information on the effectiveness of drugs under development designed to interfere with 
specific cell death mechanisms targeting nigral neurons. 
 
 Considering clinical manifestation and pathological features, subtypes of patients may be 
identified: we performed LDA in order to classify our patients in terms of age at onset, that 
is, in our opinion, the major factor of patients heterogeneity. We found 7 spots whose 
volumes statistically changed in the Early Onset (EO) and Late Onset (LO) PD groups, and a 
function able to correctly classify EO PD patients with the same "leave-one-out" procedure 
used for the predictive models. 
 
 Specific stimulation of dopamine receptors has important effects on T-cell proteome in 
patients under long term treatment with dopamine agonists. In fact, the level of 2 proteins 
was modified by levodopa and the level of 7 spots was modified by dopamine agonists 
therapy: this demonstrates that these cells are sensitive to long term dopaminergic 






 In order to validate the results obtained by the proteomic approach with an independent 
technique, we conducted Western Blot quantifications on the same samples used for the 2-
DE maps in order to clarify double identifications and verify those changes that seemed more 
significant. Two proteins of the model were chosen to this purpose: transaldolase and beta 
fibrinogen. Western blot confirmed the proteomic results and clarified how the isoform 
pattern changed in relation with PD. 
 
 The presence of large amount of fibrinogen in T cells seemed so interesting, and spots 
corresponding to FGB were so important for the predictivity of the models (they also 
correlate with disease progression), that we decided to investigate this protein more deeply. 
FGB is not synthesized neither by T cells neither by other PBMC. Moreover, it is present 
inside the cells and it is not (exclusively) associated to the cell surface. It appears to be 
internalized from plasma, but the mechanism of internalization is not clear so far, neither the 
reasons why T cells from PD patients internalize it in a decreased amount.  
 
 Next step of this research is leading the current finding about the predictive models to the 
clinical practice. This objective will be reached only through large collaborative networks, 
that will allow us to select large cohorts of subjects with high heterogeneity in terms of 
gender, age, ethnicity, clinical phenotype; the use of a different, less time consuming and 
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